Introduction {#s1}
============

Celiac disease (CD) is a common chronic disease and even though most often diagnosed in early childhood, it can present itself at any age. Most of the individuals with CD remain undiagnosed and an estimated 2% of the Swedish population is affected without having been diagnosed [@pone.0070174-Myleus1]. Ongoing disease will increase the overall risk for developing other chronic inflammatory diseases, neurological manifestations and malnutrition disorders. CD is the only autoimmune disorder where the actual genes responsible for the association in HLA are known (*HLA-DQA1* and *HLA-DQB1*) [@pone.0070174-Sollid1]. In the past few years Genome Wide Association Studies (GWAS) have had tremendous success in identifying new genes, or gene regions, that influence common diseases. These studies use several hundreds of thousands of genetic markers (single nucleotide polymorphisms, SNPs) across all human chromosomes in order to pin down the chromosomal locations of genes, which could influence the disease.

A large joint effort has been done, not the least in CD, and 40 new CD-associated genetic regions marked by SNPs have been discovered [@pone.0070174-Dubois1]--[@pone.0070174-Zhernakova1]. However, these genes cannot account for all CD heritability, and part of the genetic variance that influences disease development is still unknown [@pone.0070174-Kumar1].

Most GWAS so far have been performed on case control samples. A case control study design has some advantages compared to using a family study design. For example, in a case control design it is possible to select a perfectly matched set of controls to increase the chance of discovering susceptibility genes, and furthermore, cases and controls are usually easier to collect than individuals from the same family. However, using a family material can be a very good complement to a case control design. First of all, families with several affected members are likely to have a stronger genetic component compared to sporadic cases. Familial cases tend to be enriched for disease-predisposing alleles and there is an increased power especially for detecting rare genetic variants [@pone.0070174-Risch1]. Another important fact is that statistical analyses based on family data are robust against population stratification. Already in their paper from 1996, Risch and Merikangas suggested that all sib-pair families collected for non-parametric linkage analysis in complex diseases, should be re-run "Genome-Wide" using SNP markers and the potentially more powerful Transmission Disequilibrium Test (TDT) [@pone.0070174-Risch2]. The TDT test in sib-pairs is a test of linkage in the presence of association. Hereafter we refer to whole genome sibling TDT as "Linkage GWAS".

In this study, we aimed to uncover additional genetic factors in CD by performing a Linkage GWAS using 206 affected children (sib-pairs) within 97 nuclear families using the TDT test. In addition to the Linkage GWAS we explored gene-gene interactions and pathway analyses. We also performed a non-parametric linkage (NPL) analysis and compared the results with the published linkage analysis, with microsatellite markers, performed in the same set of families previously [@pone.0070174-Naluai1]. Furthermore, quantitative PCR was used to investigate levels of gene expression in small intestinal biopsies from additional patients with CD autoimmunity (CAI) and control patients. Finally, we stratified the TDT analysis on HLA genotype. It has been shown that carrying DQB1\*02 on both chromosomes (i.e. being homozygous), confers higher risk of developing CD as compared to heterozygote individuals [@pone.0070174-Ploski1]. It is therefore conceivable that heterozygote individuals may require more additional risk factors outside HLA, in order to accumulate sufficient risk to develop CD, compared with homozygous individuals. Based on this assumption we stratified the patient in an HLA low-risk group and an HLA high-risk group. By stratifying the Linkage GWAS, we expected to uncover even more of the so-called "missing heritability" in CD. This strategy could identify different risk factors all together or perhaps a more likely scenario is that the same risk factors outside HLA would just be more common in the HLA low-risk group.

Results {#s2}
=======

Genotyping and Imputation {#s2a}
-------------------------

We included single nucleotide polymorphism (SNP) markers that had a call rate above 97%, which led to the exclusion of 1.3% of the Omni Express and 0.6% of the 660W-Quad SNP markers. Out of the 127,535,126 imputed genotypes, 88.3% had a posterior probability of over 0.95. Approximately 90% of the 944,512 SNP markers had a minor allele frequency of at least 0.01 after imputation.

Transmission Disequilibrium Test (TDT) {#s2b}
--------------------------------------

All markers from the TDT analysis are shown in [Figure 1a](#pone-0070174-g001){ref-type="fig"}. As expected, the region around the CD associated *HLA* genes on chromosome 6 showed the strongest association with the most significant p-value reaching 4.9×10^−21^ at marker rs424232. In [Table 1](#pone-0070174-t001){ref-type="table"}, we present the 35 most significant associations found outside of HLA (HLA defined as SNP markers located within 27--34 Mb on chromosome 6). The most significant finding outside of the HLA region was the marker rs12734338 on chromosome 1, including the *PPP1R12B* gene.

![Manhattanplot of the TDT p-values.\
a) The location of all genotyped SNPs on chromosomes 1--22 and X plotted on the x-axis. --log10(p-value) result for each SNP and all transmissions on the y-axis. b) The location of all genotyped SNPs on chromosomes 1--22 and X plotted on the x-axis. --log10(p-value) result for each SNP and all transmissions, to children in the low risk group, on the y-axis. c) Regional plot of association results and recombination rates, within the region surrounding *DUSP10,* generated by SNAP (<http://www.broadinstitute.org/mpg/snap/ldplot.php>). The x-axis show 500 kb around the most associated SNP. Genomic locations of genes within the region of interest (NCBI Build 36 human assembly) were annotated from the UCSC Genome Browser (arrows). The left y-axis show --log10(p-value) and estimated recombination rates (cM/Mb) from HapMap Project (NCBI Build 36) are shown in light blue lines.](pone.0070174.g001){#pone-0070174-g001}
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###### Transmission Disequilibrium Test (TDT).

![](pone.0070174.t001){#pone-0070174-t001-1}

                                                                                                             TDT (PLINK)   exp TDT                                                                                              
  ---- ------------ ------------------------------------------------------------------- ----------- --- --- ------------- --------- ---------- -------- -------- ------ ---------- -------------------------------------------- ---------------------------------
  1     rs12734338                          PPP1R12B SYT2 UBE2T                          200736346   C   T       39          90      7.11E-06   61.44    132.45   0.46   3.41E-07                    *0,0095*                   
  10    rs10886159                         EMX2OS RAB11FIP2 EMX2                         119603600   C   T       24          50      2.51E-03   40.16    98.48    0.41   7.30E-07     0,19[\*](#nt106){ref-type="table-fn"}     
  21    rs10439884                            BAGE2 TPTE BAGE                             9993822    A   G       10          23      2.36E-02   15.52    55.78    0.28   1.86E-06     0,22[\*](#nt106){ref-type="table-fn"}     
  14    rs1958589                           EAPP SNX6 C14orf147                          33914127    C   T       15          36      3.28E-03   27.25    73.64    0.37   3.87E-06     0,32[\*](#nt106){ref-type="table-fn"}     
  17    rs17760268                              ANKFN1 NOG                               51966290    C   T       27          11      9.44E-03   57.24    17.45    3.28   4.13E-06     0,33[\*](#nt106){ref-type="table-fn"}          Cannabis depend./height
  4     rs1032355                          RG9MTD2 C4orf17 MTTP                          100758919   C   T       33          81      6.94E-06   35.07    85.28    0.41   4.74E-06   *0,0069* [\*](#nt106){ref-type="table-fn"}  
  22    rs4911642                            CCT8L2 psiTPTE22                            14884399    C   T       20          38      1.81E-02   34.38    84.15    0.41   4.86E-06     0,21[\*](#nt106){ref-type="table-fn"}           HIV-1 viral setpoint
  20     rs157640                                  DOK5                                  52847946    G   T       71          135     8.23E-06     72      138     0.52   5.25E-06                      0,38                              Functional MRI
  1     rs2068824                                  NAV1                                  199861288   C   T        2          16      9.67E-04    6.83    36.77    0.19   5.75E-06     0,014[\*](#nt106){ref-type="table-fn"}    
  3     rs2605393                                  STAC                                  36384605    G   T       40          83      1.06E-04   58.52    118.88   0.49   5.86E-06     0,13[\*](#nt106){ref-type="table-fn"}     
  19    rs2664156                       KLK2 KLK3 KLKP1 KLK4 KLK15                       56068975    C   T       48          16      6.33E-05   91.96    40.01    2.30   6.13E-06     0,34[\*](#nt106){ref-type="table-fn"}              Prostate cancer
  16     rs195656                                  HYDIN                                 69604985    A   G       18          34      2.65E-02   29.79    76.09    0.39   6.83E-06     0,52[\*](#nt106){ref-type="table-fn"}     
  11    rs4930144    IGF2AS TH MRPL23 TNNT3 SYT8 ASCL2 TNNI2LSP1 IGF2 INS-IGF2 INS H19    2005064    A   G       62          32      1.97E-03   116.06   57.04    2.03   7.28E-06     0,38[\*](#nt106){ref-type="table-fn"}      Prostate cancer/Type 1 diabetes
  4     rs17029173                         RG9MTD2 C4orf17 MTTP                          100728344   G   T       27          70      1.27E-05   27.06    71.49    0.38   7.65E-06   *0,0069* [\*](#nt106){ref-type="table-fn"}  
  4     rs13128441                                STK32B                                  5213290    C   T       32          77      1.63E-05     32       79     0.41   8.16E-06     0,74[\*](#nt106){ref-type="table-fn"}          Coronary heart disease
  3     rs1871350                                  STAC                                  36348769    C   T       27          69      1.81E-05   27.06    71.19    0.38   8.49E-06     0,13[\*](#nt106){ref-type="table-fn"}     
  3     rs2046000                                  STAC                                  36327368    A   C       28          72      1.08E-05   28.05    72.46    0.39   9.42E-06     0,13[\*](#nt106){ref-type="table-fn"}     
  17    rs7209752                    CCDC144C LOC284194 SPECC1 AKAP10                    19909989    A   G        9          26      4.06E-03   12.61    46.46    0.27   1.06E-05     0,75[\*](#nt106){ref-type="table-fn"}     
  1     rs3795277                          KIAA1751 PRKCZ GABRD                           1970978    A   C       20           8      2.33E-02   46.62    12.76    3.65   1.11E-05     0,52[\*](#nt106){ref-type="table-fn"}             Reasoning/height
  2     rs10203748                   TGFBRAP1 C2orf49 NCK2 FHL2 GPR45                    105442542   C   T       20          43      3.76E-03   23.93    65.35    0.37   1.17E-05     0,013[\*](#nt106){ref-type="table-fn"}                  AIDS
  11     rs318966                                   NTM                                  130871348   A   G       15          42      3.49E-04   33.86    80.79    0.42   1.17E-05     0,015[\*](#nt106){ref-type="table-fn"}            Asperger disorder
  6     rs9402234                             TMEM200A SAMD3                             130869175   C   T       17           7      4.12E-02   49.86    14.87    3.35   1.37E-05     0,38[\*](#nt106){ref-type="table-fn"}                  height
  9     rs1536689              C9orf93 BCN2[a](#nt107){ref-type="table-fn"}              16119630    A   G       42          18      1.95E-03   97.95    46.04    2.13   1.52E-05     0,097[\*](#nt106){ref-type="table-fn"}          HbA1c/glucose lecvels
  4     rs6838036                            DC2 AGXT2L1 RPL34                           109630528   A   C       106         57      1.24E-04   127.72   67.47    1.89   1.62E-05   *0,0048* [\*](#nt106){ref-type="table-fn"}  
  3     rs17283813                                  LPP                                  190122389   A   G       11          26      1.37E-02   17.51    53.96    0.32   1.62E-05     0,082[\*](#nt106){ref-type="table-fn"}        ***IgE/vitiligo/Celiac***
  3     rs1871352                                  STAC                                  36329541    A   C       27          69      1.81E-05   27.99    70.79    0.40   1.66E-05     0,13[\*](#nt106){ref-type="table-fn"}     
  1     rs12747934                                 FOXD3                                 63540185    A   G       20          57      2.48E-05   24.88    65.59    0.38   1.87E-05     0,68[\*](#nt106){ref-type="table-fn"}     
  1     rs4323662                          LOC100288079 IVNS1ABP                         183697117   G   T       41          22      1.67E-02   98.41    46.85    2.10   1.89E-05     0,032[\*](#nt106){ref-type="table-fn"}    
  3     rs1842149                                  STAC                                  36366714    G   T       51          17      3.74E-05   61.29    22.22    2.76   1.91E-05     0,13[\*](#nt106){ref-type="table-fn"}     
  19    rs3814892           PALM HCN2 C19orf21 POLRMT FSTL3 PRSSL1 RNF126 FGF22           589853     A   G       11          31      2.03E-03   23.45    63.03    0.37   2.08E-05     0,88[\*](#nt106){ref-type="table-fn"}     
  3     rs12631757                                 THRB                                  24618577    C   T       38          15      1.58E-03   80.09    34.53    2.32   2.09E-05     0,22[\*](#nt106){ref-type="table-fn"}       Hematol. and biochem. traits
  10    rs7097380                                 SORCS1                                 108671659   A   G       118         60      1.38E-05    119       62     1.92   2.27E-05     0,20[\*](#nt106){ref-type="table-fn"}           HbA1c/glucose lecvels
  1     rs12734001                          PPP1R12B SYT2 UBE2T                          200657537   C   T       75          40      1.10E-03   129.09   69.46    1.86   2.32E-05     0,012[\*](#nt106){ref-type="table-fn"}    
  10    rs17094083                                 GFRA1                                 117850841   C   T       27          68      2.59E-05   30.84    74.17    0.42   2.35E-05     0,27[\*](#nt106){ref-type="table-fn"}     
  3     rs12632771                                CX3CR1                                 39223856    A   G       36           8      2.43E-05     36       8      4.50   2.43E-05     0,21[\*](#nt106){ref-type="table-fn"}     

The top 35 associated SNPs are listed together with the surrounding genes defined by either Grail ([www.broadinstitute.org/mpg/grail/](http://www.broadinstitute.org/mpg/grail/)) or the Genome Browser (<http://genome.ucsc.edu/>). The disease associations are acquired from the "Catalog of Published Genome-Wide Association Studies" (<http://www.genome.gov/gwastudies/>).

For PLINK: genotypes were imputed if any of the posterior probabilities were \>0.95.

For expTDT: T and U are the expected transmission counts (based on all the posterior imputation probabilities).

NPL -- the most significant Non Parametric Linkage (NPL) p-value for the same locus as the SNP. P-values below 0.05 are marked in italics.

T and U -- the number of heterozygous parents who transmit the alleles A1 and A2, respectively. T/U -- transmission odds based on the expected transmission counts.

the marker in the set of SNPs from the linkage analysis closest to the marker in the SNP column (when this marker was not run in the linkage analysis).

closest known gene. located \>500 kb from associated SNP.

HLA Stratified Transmission Disequilibrium Test (TDT) {#s2c}
-----------------------------------------------------

In [Figure 1b](#pone-0070174-g001){ref-type="fig"} and [Table 2](#pone-0070174-t002){ref-type="table"}, we present results from the TDT analysis stratified on the *HLA-DQ* risk factor. For this analysis 115 affected offspring trios were included in the "low-risk" group and 88 trios were put in the "high-risk" group. A region including the *DUSP10* gene (also known as *MKP5*) reached genome-wide significance (p-value = 3.8×10^−8^) in the low-risk group. [Figure 1c](#pone-0070174-g001){ref-type="fig"} presents this region including the most associated SNPs plotted on the x-axis using SNAP.

10.1371/journal.pone.0070174.t002

###### HLA stratified Transmission Disequilibrium Test (TDT).

![](pone.0070174.t002){#pone-0070174-t002-2}

                                                                                            High Risk   Low risk             All                                                                                                           
  ----- -------------- ----------------------------------------- ------------- ----- ----- ----------- ---------- -------- -------- ------------ ------ ------ -------- --------- ------------ --------- ------- ------ -------- --------- ------------
  *1*    *rs12144971*                  *DUSP10*                   *220099108*   *C*   *T*     *26*        *35*     *0.74*   *1.33*   *2.49E-01*   *87*   *28*   *3.11*   *30.27*   *3.76E-08*   *20.24*   *116*   *64*   *1.81*   *15.02*   *1.06E-04*
  *1*    *rs4240931*                   *DUSP10*                   *220105678*   *T*   *C*     *26*        *35*     *0.74*   *1.33*   *2.49E-01*   *87*   *28*   *3.11*   *30.27*   *3.76E-08*   *20.24*   *116*   *64*   *1.81*   *15.02*   *1.06E-04*
  10      rs1247697                      SVIL                      29901347      C     A       41          35       1.17     0.47     4.91E-01     22     69     0.32     24.27     8.35E-07     13.44     63     104     0.61     10.07     1.51E-03
  1       rs4846734                     DUSP10                     220139621     G     A       20          25       0.80     0.55     4.56E-01     53     15     3.53     21.24     4.06E-06     13.00     76      41     1.85     10.47     1.21E-03
  10      rs7097380                     SORCS1                     108671659     A     G       46          34       1.35     1.8      1.80E-01     72     26     2.77     21.59     3.37E-06     12.70     118     60     1.97     18.90     1.38E-05
  2       rs6755308                      PRKCE                     46083771      A     G       11          33       0.33      11      9.11E-04     32     8      4.00     14.40     1.48E-04     12.62     43      41     1.05     0.05      8.27E-01
  1       rs11811613                    DUSP10                     220122026     G     A       19          25       0.76     0.82     3.66E-01     54     17     3.18     19.28     1.13E-05     12.22     76      43     1.77     9.15      2.49E-03
  2       rs13017044                     PRKCE                     46086853      A     G       12          39       0.31    14.29     1.56E-04     43     18     2.39     10.25     1.37E-03     12.09     55      57     0.96     0.04      8.50E-01
  10      rs11193120                    SORCS1                     108678768     G     A       50          35       1.43     2.64     1.04E-01     70     26     2.69     20.17     7.10E-06     11.94     120     61     1.97     19.23     1.16E-05
  1       rs11102146                     KCNA3                     111007559     C     T       13          17       0.76     0.53     4.65E-01     48     15     3.20     17.29     3.22E-05     11.88     61      34     1.79     7.67      5.60E-03
  10      rs4748417                  STAM TMEM236                  17819812      T     C        2          0         NA       2       1.57E-01     18     2      9.00     12.80     3.47E-04     11.82     20      2      10.0     14.73     1.24E-04
  2       rs4972810           DLX1 DLX2 PDK1 MAP1D ITGA6           172926135     A     G       15          11       1.36     0.61     4.33E-01     41     11     3.73     17.31     3.18E-05     11.74     56      22     2.55     14.82     1.18E-04
  3       rs1871352                      STAC                      36329541      A     C       15          25       0.60     2.5      1.14E-01     12     44     0.27     18.29     1.90E-05     11.71     27      69     0.39     18.38     1.81E-05
  3       rs1871350                      STAC                      36348769      C     T       15          25       0.60     2.5      1.14E-01     12     44     0.27     18.29     1.90E-05     11.71     27      69     0.39     18.38     1.81E-05
  10      rs10884387                    SORCS1                     108682142     T     C       43          33       1.30     1.32     2.51E-01     71     27     2.63     19.76     8.80E-06     11.70     114     60     1.90     16.76     4.25E-05
  3       rs2046000                      STAC                      36327368      A     C       15          27       0.56     3.43     6.41E-02     13     45     0.29     17.66     2.65E-05     11.68     28      72     0.39     19.36     1.08E-05
  1       rs12734338              PPP1R12B SYT2 UBE2T              200736346     C     T       20          36       0.56     4.57     3.25E-02     18     53     0.34     17.25     3.27E-05     11.66     39      90     0.43     20.16     7.11E-06
  22      rs1296826          BID BCL2L13 SLC25A18 ATP6V1E1         16459518      C     T        3          9        0.33      3       8.33E-02     3      23     0.13     15.38     8.77E-05     11.47      6      32     0.19     17.79     2.47E-05
  4       rs7687176                  INTS12 GSTCD                  106746555     T     C       10          7        1.43     0.53     4.67E-01     2      24     0.08     18.62     1.60E-05     11.47     12      31     0.39     8.40      3.76E-03
  2       rs4972809           DLX1 DLX2 PDK1 MAP1D ITGA6           172925337     A     G       16          12       1.33     0.57     4.50E-01     41     11     3.73     17.31     3.18E-05     11.45     57      23     2.48     14.45     1.44E-04
  6       rs13207543              ELOVL4 SH3BGRL2 TTK              80592601      A     C       13          26       0.50     4.33     3.74E-02     52     19     2.74     15.34     8.99E-05     11.44     65      45     1.44     3.64      5.65E-02
  4       rs1032355              RG9MTD2 C4orf17 MTTP              100758919     C     T        9          42       0.21    21.35     3.82E-06     24     37     0.65     2.77      9.60E-02     11.23     33      81     0.41     20.21     6.94E-06
  5       rs11952677                 SCAMP1 LHFPL2                 77823690      G     A       27          34       0.79     0.80     3.70E-01     55     17     3.24     20.06     7.52E-06     11.23     84      51     1.65     8.07      4.51E-03
  1       rs12743521                    DUSP10                     220167571     A     G       21          24       0.88     0.2      6.55E-01     50     15     3.33     18.85     1.42E-05     11.22     74      40     1.85     10.14     1.45E-03
  12      rs11068315             FBXW8 HRK TESC RNFT2              115994935     T     C        8          6        1.33     0.28     5.93E-01     4      26     0.15     16.13     5.90E-05     11.09     12      32     0.38     9.09      2.57E-03
  6       rs7745052     FBXL4 C6orf168 USP45 COQ3 POU3F2 SFRS18    99747331      A     G       54          17       3.18    19.28     1.13E-05     32     25     1.28     0.86      3.54E-01     11.08     86      42     2.05     15.12     1.01E-04
  12      rs17245501                    PPFIA2                     80260470      C     T       17          18       0.94    0.028     8.66E-01     45     13     3.46     17.66     2.65E-05     11.02     62      31     2.00     10.33     1.31E-03
  1       rs7544501                     DUSP10                     220168985     T     C       21          24       0.88     0.2      6.55E-01     51     16     3.19     18.28     1.90E-05     11.02     75      41     1.83     9.97      1.60E-03
  1        rs785627                      LPHN2                     82521165      T     C       30          17       1.77     3.60     5.79E-02     25     61     0.41     15.07     1.04E-04     11.02     56      79     0.71     3.92      4.78E-02
  8        rs720131                      RAD21                     117985196     A     G       35          40       0.88     0.33     5.64E-01     79     34     2.32     17.92     2.30E-05     10.90     115     75     1.53     8.42      3.71E-03
  12      rs11104365                    MGAT4C                     86164650      C     T       41          57       0.72     2.61     1.06E-01     34     79     0.43     17.92     2.30E-05     10.81     77     136     0.57     16.34     5.29E-05
  14      rs7144018              NAT12 EXOC5 C14orf108             56676820      C     T       29          3        9.67    21.12     4.30E-06     14     20     0.70     1.06      3.04E-01     10.79     45      23     1.96     7.12      7.63E-03

The top 32 associated SNPs from the results of the HLA stratified analysis. Surrounding genes are defined by either Grail ([www.broadinstitute.org/mpg/grail/](http://www.broadinstitute.org/mpg/grail/)) or the Genome Browser (<http://genome.ucsc.edu/>). The low risk group consists of 115 trios and the high risk group of 88 trios. Genotypes were imputed if any of the posterior probabilities were \>0.95.

Chisq -- the value of the TDT test statistic for the transmission counts.

Weighted Chisq -- based on the transmission counts of the low and high-risk groups. This value is used for ranking the results.

T and U -- the number of heterozygous parents who transmit the alleles A1 and A2, respectively. T/U -- transmission odds based on the expected transmission counts.

Interaction Analyses {#s2d}
--------------------

Since some markers just below genome-wide significance are still expected to be true findings, we wanted to try and separate these from the, in fact, true negative findings (those that show linkage and association close to genome-wide significance just by chance). In total, 603 SNP markers from 383 independent regions and their surrounding genes were identified by three inclusion criteria ([Fig. 2](#pone-0070174-g002){ref-type="fig"} and [Table S1](#pone.0070174.s001){ref-type="supplementary-material"}). These genes were subsequently used for pathway and two-locus interaction analyses.

![Illustration of the three inclusion criteria used for pathway and interaction analyses.\
*The first criteria* of p-values less than 3.0×10^−4^ in the linkage TDT analysis resulted in a total of 477 markers. *The second criteria* included a comparison of the results from this study with the results from the study by Dubois et al. [@pone.0070174-Dubois1]. We included 118 SNPs that had a simple score based on a combined p-value less than 5.0×10^−5^ and in the same allelic direction in both datasets. *The third criteria* involved selecting markers with a large effect size. We included 65 markers which had a ratio of transmitted versus not transmitted (T/NT) alleles of over 5 or below 0.2, combined with a p-value of less than 2.0×10^−3^.](pone.0070174.g002){#pone-0070174-g002}

### Two-locus interaction analysis {#s2d1}

Two-locus interaction analysis, identified 582 SNP pairs with a p-value of less than 1.0×10^−4^ for the test comparing the model M~0~ of no association and the general two-locus model M~G~. Out of these, 101 pairs from 87 regions deviated significantly (p\<0.05) from a purely multiplicative model (M~M~), which is the best fitting model when at least one of the SNP markers is false. Under the null hypothesis we expect to find 29 such pairs. The 101 pairs showed either epistasis (individuals carry both risk alleles) or evidence of heterogeneity (individuals carry either the one or the other risk allele from the two loci).

The results with a p-value \<1.0×10^−4^ for epistasis and those with high p-value (\>0.05), which represent pairs that did not show convincing deviation from the heterogeneity model are listed in [Table 3](#pone-0070174-t003){ref-type="table"} and [4](#pone-0070174-t004){ref-type="table"}. Several loci were in an epistatic relationship with HLA; rs4899272 (*ACTN1*), rs1073933 (*COX7C*), rs10482751 (*TGFB2*), rs571879 (*APPL1*) and rs7590305 (*FABP1*). Also, previously identified susceptibility loci for CD were involved in several interactions: rs4899272 (*ACTN1*), rs6741418 (*STAT1, GLS*), rs13096142 (*CCR1,2,3,5*), rs10197319 (*ICOS, CTLA4*) and rs870875 (*CD247*).

10.1371/journal.pone.0070174.t003

###### The top epistasis interaction results from the 101 two-locus interaction analysis.

![](pone.0070174.t003){#pone-0070174-t003-3}

  *Snp 1*                         *Genes*                      chr     *Snp 2*                    *Genes*                  chr   *N*     *P~02~*     *P~12~*     *P~M2~*
  ------------ ---------------------------------------------- ----- ------------- --------------------------------------- ----- ------ ----------- ------------ ----------
  rs2187668                        HLADQ                        6    *rs4899272*                  *ACTN1*                  14    *95*   *4.0E-17*   *1.42E-13*   *4.E-02*
                                                                     *rs204034*                  *SHISA9*                  16    *94*   *1.3E-14*   *1.09E-12*   *5.E-02*
                                                                      rs571879       APPL1 HESX1 IL17RD. DNHD2. ASB14       3     94     2.3E-15     5.21E-11     3.E-02
  rs204999                          HLA                         6     rs1073933                    COX7C                    5     94     9.9E-14     9.27E-12     3.E-02
                                                                     rs11836636               ATXN7L3B KCNC2               12    *91*   *1.1E-12*   *8.15E-11*   *4.E-02*
  rs7745052     FBXL4. C6orf168. USP45. COQ3. POU3F2. SFRS18    6                                                                 92     2.3E-05     1.79E-05     4.E-02
  rs10749738                       FOXD3                        1     rs1373649                   BMPR1B                    4     93     2.7E-05     1.78E-05     4.E-02
  rs3860295                     RASSF5 IKBKE                    1    rs13096142           CCR5 CCR3 LTF CCR2 CCR1           3     95     1.1E-05     6.48E-06     1.E-02
  rs9396802                 KIF13A NUP153 FAM8A1                6     rs2194633                    NETO1                   18     95     3.8E-06     6.82E-06     2.E-02
  rs9296204                      MTCH1 PI16                     6     rs4385459        LY96 JPH1 GDAP1 TMEM70 TCEB1         8     95     2.8E-05     9.91E-06     3.E-02
  rs9397928       ARID1B[\*](#nt113){ref-type="table-fn"}       6     rs2415836    FSCB[\*](#nt113){ref-type="table-fn"}   14     93     2.8E-05     1.75E-05     3.E-03
  rs1145212                  APOA5 ZNF259 BUD13                11    rs10083673                    MYO5A                   15     95     6.6E-05     1.77E-05     2.E-03
  rs7756191                        DNAH8                        6     rs1108001           NAV2 HTATIP2 DBX1 PRMT3          11     95     3.5E-05     2.60E-05     3.E-03
  rs10197319                     ICOS CTLA4                     2     rs882820                   SRL TFAP4                 16     94     1.4E-05     3.03E-05     3.E-05
  rs4899272                        ACTN1                       14    rs17703807                  C15orf41                  15     83     2.9E-05     8.68E-05     1.E-02

All SNP pairs which reached an interaction p-value of P~12~\<1.0×10^−4^, in addition to P~M2~\<0.05.

closest known gene. located \>500 kb from associated SNP.

P~02~-- p-value for the test statistic comparing the models M~0~ (no association) and the general model M~G~.

P~12~-- p-value for the test test comparing the models M~R~ (heterogeneity) and the general model M~G~.

P~M2~-- p-value for the test comparing the models M~M~ (multiplicative) and the general model M~G~.

10.1371/journal.pone.0070174.t004

###### The top heterogeneity results from the 101 two-locus interaction analysis.

![](pone.0070174.t004){#pone-0070174-t004-4}

  *SNP1*                       *Genes*                   *chr*     *SNP2*                                  *Genes*                                *chr*   *N*   *P~02~*   *P~12~*    *PM2*
  ------------ ---------------------------------------- ------- ------------ ------------------------------------------------------------------- ------- ----- --------- ---------- --------
  rs4899272                     ACTN1                     14     rs4820682           SRRD HPS4 TFIP11 ASPHD2 MIR548JTPST2 CRYBB1 CRYBA4            22     95    7.1E-06   6.97E-02   2.E-02
                                                                 rs4426448                                  DOK6                                   18     94    9.5E-06   6.80E-01   1.E-02
                                                                  rs870875                                  CD247                                   1     94    9.4E-05   7.19E-02   3.E-02
                                                                 rs4842007                                  PAEP                                    9     95    8.6E-06   5.66E-01   4.E-02
  rs571879          APPL1 HESX1 IL17RDDNHD2 ASB14          3     rs4385459                      LY96 JPH1 GDAP1 TMEM70 TCEB1                        8     94    4.1E-05   5.81E-01   5.E-02
  rs7590305                  FABP1 THNSL2                  2      rs390495                                 MICAL3                                  22     93    7.0E-05   9.09E-01   3.E-03
  rs7745052     FBXL4 C6orf168 USP45COQ3 POU3F2 SFRS18     6     rs4930144    IGF2AS TH MRPL23 TNNT3 SYT8 ASCL2TNNI2 LSP1 IGF2 INS-IGF2 INS H19    11     50    1.9E-05   5.30E-01   3.E-02
  rs10749738                    FOXD3                      1     rs10498982                EPHA7[\*](#nt118){ref-type="table-fn"}                   6     93    2.0E-05   1.95E-01   4.E-02
                                                                 rs2605393                                  STAC                                    3     63    7.3E-05   4.37E-01   4.E-02
  rs2187668                     HLADQ                      6     rs11013804                               KIAA1217                                 10     94    3.5E-14   8.40E-02   2.E-02
                                                                 rs1676235                           ESRRB ANGEL1 VASH1                            14     43    2.0E-07   8.55E-02   3.E-02
  rs958802                KANK4 L1TD1 INADL                1     rs2194633                                  NETO1                                  18     95    1.9E-05   5.55E-01   3.E-02
  rs2345981                    KHDRBS2                     6     rs6495130                                  RYR3                                   15     94    6.1E-05   1.58E-01   3.E-02
  rs11940562    PCDH7[\*](#nt118){ref-type="table-fn"}     4     rs4905043                               ITPK1 CHGA                                14     44    4.6E-05   2.77E-01   2.E-02
  rs4656538                     POU2F1                     1     rs2187668                                  HLADQ                                   6     94    3.0E-13   1.19E-01   5.E-02
  rs3860295                  RASSF5 IKBKE                  1     rs7046385                                  SMC2                                    9     94    5.3E-05   1.07E-01   2.E-02
  rs6741418                STAT1 GLS STAT4                 2     rs10798004                     C1orf25 C1orf26 IVNS1ABP RNF2                       1     87    7.2E-05   7.68E-02   4.E-02
                                                                 rs1571812                                  VLDLR                                   9     86    3.0E-05   9.19E-02   4.E-02
                                                                  rs882820                                SRL TFAP4                                16     87    4.2E-05   3.52E-01   6.E-03
                                                                 rs1470379                                   VIM                                   10     82    1.0E-05   3.70E-01   8.E-03
                                                                 rs10946659                              DCDC2 NRSN1                                6     87    1.9E-06   6.64E-01   9.E-03
  rs10482751                    TGFB2                      1     rs1571812                                  VLDLR                                   9     92    5.2E-05   1.86E-01   1.E-02

All SNP pairs which reached an interaction p-value of P~12~\>0.05, in addition to P~M2~\<0.05.

closest known gene located \>500 kb from associated SNP.

P~02~-- p-value for the test statistic comparing the models M~0~ (no association) and the general model M~G~.

P~12~-- p-value for the test test comparing the models M~R~ (heterogeneity) and the general model M~G~.

P~M2~-- p-value for the test comparing the models M~M~ (multiplicative) and the general model M~G~.

### Pathway analysis {#s2d2}

Biological functions clustered by Ingenuity Pathway Analysis (IPA) and Genetrail [@pone.0070174-Backes1] are shown in [Table 5](#pone-0070174-t005){ref-type="table"}, [6](#pone-0070174-t006){ref-type="table"} and [7](#pone-0070174-t007){ref-type="table"}. Several clusters were significant after correction for multiple comparisons. The most significant network implicated by IPA included *DUSP10* ([Fig. 3](#pone-0070174-g003){ref-type="fig"} and [Table 8](#pone-0070174-t008){ref-type="table"}). The second top network included the MHC complex (HLA) and the third top network included *LPP,* which is located within the most significantly non-HLA associated region identified in CD so far [@pone.0070174-Dubois1].

![Ingenuity network 1.\
The top network identified by the Ingenuity IPA software using genes surrounding all 603 most associated SNPs from the TDT analysis. Molecules in gray were present among the genes from our TDT analysis and molecules in white were added by the IPA software. The *DUSP10* gene is marked in yellow.](pone.0070174.g003){#pone-0070174-g003}

10.1371/journal.pone.0070174.t005

###### Biological functions of genes surrounding the 603 top associated SNPs. Results from IPA.

![](pone.0070174.t005){#pone-0070174-t005-5}

  FunctionAnnotation                         p-value(Raw)   B-H p-value[\*](#nt124){ref-type="table-fn"}                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         Molecules                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         Molecules
  ----------------------------------------- -------------- ---------------------------------------------- --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- -----------
  non-insulin-dependent diabetes mellitus     0.0000057                        0.025                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        ABCC8. ADRA1B. ADRA1D. AGT. APOA5. ATP10A. BCL2L11. CCR5. CD38. CNTNAP2. FOXP1. FTO. HFE. HFE2. INS. INSR. KCNJ11. KIRREL3. KLF10. mir-154. mir-448. MTTP. PBX3. PIEZO2. PPARA. PPP3CA. PRDM10. RGS5. VEGFA. ZMYM2                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        30
  quantity of metal                           0.0000082                        0.025                                                                                                                                                                                                                                                                                                                                                                                                                                                             ABCC8. ADRA1B. AGT. APLP2. ATP2B3. BCL2. BMP2. BTK. CAMLG. CCR5. CD247. CD38. CHGA. CX3CR1. CXCL13. DARC. DCN. DVL1. EGF (includes EG:13645). FBXL5. FCER1A. GNA14. GNB1. HFE. HFE2. IGF2. INS. INSR. KCNJ11. LTF. NTS. NUCB2. POMC. PRL. PRNP. PTGDR2. RGS1. RYR3. SELL. SOD1. TRPM8. TXNIP. VAV3. VEGFA                                                                                                                                                                                                                                                                                                                                                                                                                                            44
  incorporation of thymidine                   0.000010                        0.025                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                AGT. AKAP13. BMP2. CD40. EGF (includes EG:13645). IGF2. INS. INSR. PRL. THBS2. TNFSF13B. VEGFA. WT1                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               13
  quantity of Ca2+                             0.000018                        0.033                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  ABCC8. ADRA1B. AGT. ATP2B3. BCL2. BTK. CAMLG. CCR5. CD247. CD38. CHGA. CX3CR1. CXCL13. DARC. DCN. DVL1. EGF (includes EG:13645). FCER1A. GNA14. GNB1. IGF2. INS. INSR. KCNJ11. NTS. NUCB2. POMC. PRL. PRNP. PTGDR2. RGS1. RYR3. SELL. SOD1. TRPM8. VAV3. VEGFA                                                                                                                                                                                                                                                                                                                                                                                                                                                                  37
  eye development                              0.000022                        0.033                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   BID. BMPR1B. CD247. CHD7. CRYBB2. CX3CR1. DLX1. DNMT3A. EBF3. EGF (includes EG:13645). FJX1. FTO. GJA3. H19. HESX1. IFT88. IGF2. IRX3. ITGA6. LUM. MITF. OGN. PAX5. PROM1. PRRX2. PYGO1. SEMA5A. SOD1. STAT1. TGFB2. TH. THBS2. THRB. TUB. USH2A. VEGFA. WT1                                                                                                                                                                                                                                                                                                                                                                                                                                                                   37
  diabetes mellitus                            0.000027                        0.034                                                                                                                                                                                                                                                                                                                                                                                                  ABCC8. ABCG1. ABT1. ADRA1B. ADRA1D. AGT. APOA5. ATP10A. BCL2. BCL2L11. BTC. BTN2A1. BTN3A2. CBLB. CCR5. CD200. CD38. CD40. CNTNAP2. CYBA. E2F3. ENAH. FOXP1. FTO. GABRD. HFE. HFE2. HIST1H3A (includes others). HTR2C. ICOS. IGF2-AS1. INS. INSR. KCNJ11. KIRREL3. KLF10. mir-154. mir-448. MTTP. PBX3. PDE8A. PGM1. PIEZO2. PPARA. PPP3CA. PRDM10. PRSS16. PRUNE2. PXDNL. RGS1. RGS5. SELL. SOD1. TH. THRB. TSPO. VEGFA. ZMYM2                                                                                                                                                                                                                                                                                                                                                                                 58
  angiogenesis of bone                         0.000032                        0.034                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      BMP2. NOG. TGFB2. VEGFA                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      4
  quantity of metal ion                        0.000071                        0.043                                                                                                                                                                                                                                                                                                                                                                                                                                                                               ABCC8. ADRA1B. AGT. ATP2B3. BCL2. BTK. CAMLG. CCR5. CD247. CD38. CHGA. CX3CR1. CXCL13. DARC. DCN. DVL1. EGF (includes EG:13645). FCER1A. GNA14. GNB1. IGF2. INS. INSR. KCNJ11. NTS. NUCB2. POMC. PRL. PRNP. PTGDR2. RGS1. RYR3. SELL. SOD1. TRPM8. TXNIP. VAV3. VEGFA                                                                                                                                                                                                                                                                                                                                                                                                                                                              38
  development of head                          0.000069                        0.043                                                                                                                                                                                                                                                                                                                                                                                                                                                                   BCL2. BCL2L11. BID. BMP2. BMPR1B. CD247. CHD7. CRYBB2. CX3CR1. DLX1. DNMT3A. EBF3. EGF (includes EG:13645). FJX1. FTO. GJA3. H19. HESX1. IFT88. IGF2. IRX3. ITGA6. LUM. MITF. MYO5A. NOG. OGN. PAX5. PROM1. PRRX2. PYGO1. SEMA5A. SOD1. STAT1. TGFB2. TH. THBS2. THRB. TUB. USH2A. VEGFA. WT1                                                                                                                                                                                                                                                                                                                                                                                                                                                  42
  migration of cells                           0.000057                        0.043                                                                                                                                                                                 ADI1 (includes EG:104923). AGT. APLP2. APPL1. ARHGAP5. B3GAT1. BCL2. BGN. BID. BMP2. BTC. BTK. CBLB. CCR5. CD200. CD247. CD36. CD38. CD40. CD99. CHGA. CMA1. CNTNAP2. CSF2RA. CTBP2. CTNNA2. CTSG. CX3CR1. CXCL13. DARC. DCDC2. DCN. DISC1. DLX1. DYX1C1. E2F3. EBF3. EGF (includes EG:13645). ELMO2. FCER1A. FH. FHL2. GFRA1. GNA12. GRIA2. GZMB. HTATIP2. ICOS. IGF2. INS. INSR. ITGA6. KIAA0319. LAMA2. LPP. LSP1 (includes EG:16985). LTF. LUM. LY96 (includes EG:17087). MAPK1. MNX1. MTAP. MYO10. MYO1F. NAV1. NOG. NPTX2. NTS. NUCB2. PAEP. PDPN (includes EG:10630). PEX11B. PEX13. POMC. POU3F2. PPARA. PPM1F. PRKCQ. PRKCZ. PRL. PRNP. PROK2. PTGDR2. PTGES. PTK2 (includes EG:14083). PVR. RASSF5. RGS1. SATB2. SELL. SEMA5A. SOD1. STAT1. TDP2. TGFB2. THBS2. TIAM1. TNFAIP8. TNFRSF18. TNFRSF4. TNFSF13B. TSPO. UNC5C. VASH1. VAV3. VEGFA. VIM. WWOX                                                                                                                                                                108
  cell movement                                0.000073                        0.043                                                                                                                                             ADCY10. ADI1 (includes EG:104923). AGT. APLP2. APPL1. ARHGAP5. B3GAT1. BCL2. BGN. BID. BMP2. BTC. BTK. CATSPER3. CBLB. CCR5. CD200. CD247. CD36. CD38. CD40. CD99. CHGA. CMA1. CNTNAP2. CSF2RA. CTBP2. CTNNA2. CTSG. CX3CR1. CXCL13. DARC. DCDC2. DCN. DISC1. DLX1. DYX1C1. E2F3. EBF3. EGF (includes EG:13645). ELMO2. ENAH. FCER1A. FH. FHL2. GFRA1. GNA12. GNB1. GRIA2. GZMB. HTATIP2. ICOS. IFT88. IGF2. INS. INSR. ITGA6. KIAA0319. LAMA2. LPP. LSP1 (includes EG:16985). LTF. LUM. LY96 (includes EG:17087). MAPK1. MNX1. MTAP. MYO10. MYO1F. NAV1. NCK2. NOG. NPTX2. NTS. NUCB2. PAEP. PDPN (includes EG:10630). PEX11B. PEX13. POMC. POU3F2. PPARA. PPM1F. PRKCQ. PRKCZ. PRL. PRNP. PROK2. PTGDR2. PTGES. PTK2 (includes EG:14083). PVR. RASSF5. RGS1. RGS10. SATB2. SELL. SEMA5A. SOD1. SPAG16. STAT1. TAS1R3. TDP2. TGFB2. THBS2. THRB. TIAM1. TNFAIP8. TNFRSF18. TNFRSF4. TNFSF13B. TSPO. UNC5C. VASH1. VAV3. VEGFA. VIM. WWOX                                                                                                                            118
  apoptosis                                    0.000069                        0.043                       ABCG1. ADCY10. ADI1 (includes EG:104923). ADRA1B. ADRA1D. AGPAT2. AGT. APPL1. ATXN1. BCL2. BCL2L11. BCL2L13. BGN. BID. BIK. BMP2. BMPR1B. BTC. BTK. CACNA1A. CBLB. CCDC86. CCNI. CCNL2. CCR5. CD200. CD247. CD36. CD38. CD40. CD5L. CD99. CDK11A/CDK11B. CSF2RA. CTBP2. CTSG. CX3CR1. CYBA. DACH1. DCN. DLX1. DNMT3A. DUSP10. DVL1. E2F3. EGF (includes EG:13645). EPHA7. EPHX1. EPM2A. FABP1. FANCC. FBXL5. FCER1A. FHL2. FOXP1. FSTL3. GFRA1. GNA12. GRIA2. GZMB. HFE. HSF2. HTATIP2. ICOS. IFNE. IGF2. IKBKE. IL17RD. INS. INSR. IPPK. ITGA6. ITGB3BP. ITPK1. IVNS1ABP. KIFAP3. KLF10. LAMA2. LIG4. LSP1 (includes EG:16985). LTF. LUM. MAGED1. MAGEH1. MAPK1. mir-154. mir-506. MITF. MLLT3. MNAT1. MTCH1. NELL1. NOG. NPTX2. NTS. PAEP. PAWR. PAX5. PDCD6IP. PEX11B. PKN2. POLH. POMC. PPARA. PPM1F. PPP2R4. PPP3CA. PRAME. PRKCH. PRKCQ. PRKCZ. PRL. PRNP. PRPF19. PRUNE2. PTGES. PTK2 (includes EG:14083). PUS10. RASSF5. RGS5. RNASEH1. SELL. SGCG. SLC25A6. SMARCA2. SMOX. SOD1. SPAG16. ST14. STAT1. TFAP4. TGFB2. THBS2. TIAM1. TMEM109. TMEM132A. TNFAIP8. TNFRSF18. TNFRSF4. TNFSF13B. TREX2. TRPS1. TSPO. TUB. TXNIP. UNC5C. VEGFA. VIM. VPS13A. WT1. WWOX. XPO1. ZMYM2      153
  quantity of leukocytes                       0.000076                        0.043                                                                                                                                                                                                                                                                                                                                                               AGT. BCL2. BCL2L11. BID. BIK. BST1 (includes EG:12182). BTK. CARD11. CBLB. CCR5. CD200. CD247. CD36. CD38. CD40. CD5L. CRLF2. CX3CR1. CXCL13. DCN. DMD. DUSP10. FABP1. FANCC. FCER1A. FOXP1. GNA12. HESX1. ICOS. IGF2. INS. ITGA6. KDM5A. KIFAP3. KLF10. LAMA2. LIG4. LSP1 (includes EG:16985). LUM. NOG. PAWR. PAX5. PRKCQ. PRL. PRNP. PROK2. PTGDR2. PTGES. PTK2 (includes EG:14083). RASSF5. RGS1. RGS10. SELL. SOD1. ST14. STAM. STAT1. TNFRSF4. TNFSF13B. TOX. TXNIP. VAV3. VEGFA. VPREB1. WWOX                                                                                                                                                                                                                                                                                                                                               65

A total of 823 genes surrounding the 603 top associated SNPs were put into the IPA software.

Surrounding genes were defined by either Grail ([www.broadinstitute.org/mpg/grail/](http://www.broadinstitute.org/mpg/grail/)) or the Genome Browser (<http://genome.ucsc.edu/>). Gene families located in the same region were manually curated so that only one gene in each family remained in each region, based on a similar official gene symbol.

Hochberg Y, Benjamini Y. Statistics in medicine 1990; 9∶811--8.

10.1371/journal.pone.0070174.t006

###### Biological functions of genes surrounding the 603 top associated SNPs. Results from GeneTrail.

![](pone.0070174.t006){#pone-0070174-t006-6}

  Category             rank                     Subcategory                     expected   observed                p-value (raw)                                                                                                   Genes
  ------------------- ------ ------------------------------------------------- ---------- ---------- ----------------------------------------- -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------
                                                                                                                                               
  KEGG                  1                Type II diabetes mellitus                1.91        7                       0.0026                                                                                     ABCC8 CACNA1A INS INSR KCNJ11 MAPK1 PRKCZ
  KEGG                  2                   Salivary secretion                    3.62        9                        0.003                                                                               ADRA1B ADRA1D AMY1B ATP2B3 BST1 CALML6 CD38 CST2 RYR3
  KEGG                  3                   Pathways in cancer                   13.35        23                       0.007                                          APPL1 BCL2 BID BMP2 CBLB CSF2RA CTBP2 CTNNA2 DVL1 E2F3 EGF FGF22 FH ITGA6 LAMA2 MAPK1 MITF PTK2 RASSF5 STAT1 TCEB1 TGFB2 VEGFA
  KEGG                  4            T cell receptor signaling pathway            4.40        10                       0.012                                                                             CARD11 CBLB CD247 ICOS MAPK1 NCK2 PDK1 PPP3CA PRKCQ VAV3
  KEGG                  5               TGF-beta signaling pathway                3.46        8                        0.022                                                                                     BMP2 BMPR1B DCN ID4 MAPK1 NOG TGFB2 THBS2
  KEGG                  6         Cytokine-cytokine receptor interaction         10.79        18                       0.022                                                  BMP2 BMPR1B CCR5 CD40 CRLF2 CSF2RA CX3CR1 CXCL13 EGF IFNA6 IFNE IL3RA PRL TGFB2 TNFRSF18 TNFRSF4 TNFSF13B VEGFA
  KEGG                  7     Arrhythmogenic right ventricular cardiomyopathy     3.09        7                        0.034                                                                                     ACTN1 CTNNA2 DMD ITGA10 ITGA6 LAMA2 SGCG
                                                                                                                                               
  Gene Ontology         1       negative regulation of phosphatase activity       0.21        3                       0.0006                                                                                                PPP2R4 TGFB2 TIPRL
  Gene Ontology         2            positive regulation of apoptosis            13.93        27                      0.0008                          AGT AKAP13 ARHGEF18 BCL2 BCL2L11 BCL2L13 BID BIK BMP2 BTK CD38 HTATIP2 IKBKE ITGB3BP MAGED1 MAPK1 MTCH1 PAWR PPP2R4 PRUNE2 PVR SOD1 TFAP4 TGFB2 TIAM1 VAV3 WT1
  Gene Ontology         3           regulation of phosphatase activity            0.53        4                       0.0015                                                                                              BMP2 PPP2R4 TGFB2 TIPRL
  Gene Ontology         5            glomerular epithelium development            0.08        2                       0.0017                                                                                                     BASP1 WT1
  Gene Ontology         6                         vesicle                        12.50        24                      0.0017                                           APPL1 BGN CD36 CTSG CUZD1 CXXC4 CYBA DVL1 EGF GRIA2 HFE HPS4 LTF NRSN1 PALM RASSF9 SEC24A SOD1 SYT1 SYT2 TGFB2 TH THBS2 VEGFA
  Gene Ontology         7                cellular defense response                2.38        8                       0.0024                                                                                   CCR5 CD300C CD5L CX3CR1 DCDC2 LSP1 LY96 NCR2
  Gene Ontology         8                   cytoplasmic vesicle                  12.17        23                      0.0026                                              BGN CD36 CTSG CUZD1 CXXC4 CYBA DVL1 EGF GRIA2 HFE HPS4 LTF NRSN1 PALM RASSF9 SEC24A SOD1 SYT1 SYT2 TGFB2 TH THBS2 VEGFA
  Gene Ontology         9            phosphoinositide 3-kinase cascade            0.33        3                       0.0033                                                                                                   AGT INS TGFB2
  Gene Ontology         10                 hindbrain development                  0.37        3                       0.0048                                                                                                 CTNNA2 MYO16 SDF4
  Gene Ontology         11      regulation of neuronal synaptic plasticity        0.37        3                       0.0048                                                                                                NETO1 SHISA9 SYNGR1
  Gene Ontology         12              neuron projection membrane                0.12        2                       0.0049                                                                                                  CNTNAP2 SHISA9
  Gene Ontology         13             dopamine biosynthetic process              0.12        2                       0.0049                                                                                                     TGFB2 TH
  Gene Ontology         14        hydrogen peroxide biosynthetic process          0.12        2                       0.0049                                                                                                     CYBA SOD1
  Gene Ontology         15       positive regulation of respiratory burst         0.12        2                       0.0049                                                                                                     INS INSR
  Gene Ontology         16     cardiac epithelial to mesenchymal transition       0.12        2                       0.0049                                                                                                    BMP2 TGFB2
  Gene Ontology         17               enzyme activator activity                7.11        15                      0.0051                                                           AGT APOA5 ARHGAP5 BCL2L13 BMP2 EGF MMP17 OPHN1 PITRM1 PPP1R12B PPP2R4 RGS1 RGS5 TBC1D15 VAV3
  Gene Ontology         18      epidermal growth factor receptor signaling        0.74        4                       0.0054                                                                                                 AGT EGF NCK2 SNX6
  Gene Ontology         19                 extracellular matrix                   7.23        15                      0.0060                                                                   ASPN BGN CMA1 CPXM2 CTSG DCN ECM2 LAMA2 LUM MMP23B OGN SOD1 TGFB2 USH2A VEGFA
                                                                                                                                               
  NIA human disease     1                Diabetes Mellitus. Type 2               10.49        22      0.0003[\*](#nt126){ref-type="table-fn"}                               ABCC8 AGT AKAP10 APOA5 BTC CCR5 CD36 CMA1 CYBA FABP1 FTO INS INSR KCNJ11 MTTP PPARA PRKCZ SELL TH THBS2 TXNIP VEGFA
  NIA human disease     2                  Hyperlipoproteinemias                  0.26        3                       0.0012                                                                                                 APOA5 FABP1 PPARA
  NIA human disease     3                  Diabetic Angiopathies                  1.94        7                       0.0024                                                                                      CD40 CYBA INS KCNJ11 PPARA TXNIP VEGFA
  NIA human disease     4                   Postmortem Changes                    0.10        2                       0.0026                                                                                                     DAOA TPH2
  NIA human disease     5                   Disease Progression                   7.77        16                      0.0030                                                                 AGT BCL2 CCR5 CD40 CMA1 CX3CR1 DCN EGF HFE KCNJ11 PPARA PRNP SELL SOD1 VEGFA WT1
  NIA human disease     6                      Birth Weight                       1.69        6                       0.0054                                                                                             EGF EPHX1 FTO H19 INS TH
  NIA human disease     7       Pathological Conditions. Signs and Symptoms      23.66        34                      0.0073                    AGT APOA5 BCL2 CCR5 CD40 CMA1 CX3CR1 CYBA DAOA DCN DISC1 DMD EGF EPHX1 FCER1A FTO H19 HFE HTR2C INS INSR KCNJ11 LTF MTTP PLXNA2 POMC PPARA PRNP SELL SOD1 TH TPH2 VEGFA WT1
  NIA human disease     8                  Bronchiolitis. Viral                   0.15        2                       0.0075                                                                                                    CCR5 CX3CR1
  NIA human disease     9                  Kidney Failure. Acute                  0.15        2                       0.0075                                                                                                     CYBA WT1
  NIA human disease     10                   Diseases in Twins                    0.46        3                       0.0086                                                                                                 DISC1 HFE PLXNA2
  NIA human disease     11                Coronary Artery Disease                 4.55        10                      0.0127                                                                              AGT APOA5 CD36 CD40 CMA1 CX3CR1 CYBA PPARA THBS2 VEGFA
  NIA human disease     12                       Dyslexia                         0.26        2                       0.0233                                                                                                  DYX1C1 KIAA0319
  NIA human disease     13                 Myocardial Infarction                  6.64        12                      0.0282                                                                        AGT AKAP10 APOA5 CCR5 CTSG CX3CR1 HFE INSR MTTP THBS2 TNFRSF4 VEGFA
  NIA human disease     14          Nutritional and Metabolic Diseases           18.45        26                      0.0295                                      ABCC8 AGT AKAP10 APOA5 BTC CBLB CCR5 CD36 CMA1 CYBA DCN FABP1 FTO HTR2C INS INSR KCNJ11 MTTP POMC PPARA PRKCZ SELL TH THBS2 TXNIP VEGFA
  NIA human disease     15                      Overweight                        0.31        2                       0.0338                                                                                                     APOA5 FTO

A total of 823 genes surrounding the 603 top associated SNPs were put into the GeneTrail software. Surrounding genes were defined by either Grail (<http://www.broadinstitute.org/mpg/grail/>) or the Genome Browser (http://genome.ucsc.edu/). Gene families located in the same region were manually curated so that only one gene in each family remained in each region, based on a similar official gene symbol.

Significant after multiple testing correction using FDR adjustment. (p~corr~-value=0.032) Size of test set: 823 (768 known). Number of known ref. IDs: 44829 Kegg: Number of annotated genes in test set was 220. Number of annotated genes in ref set was 5405. Gene Ontology: Number of annotated genes in test set was 476. Number of annotated genes in ref set was 11580.

NIA human genes sets: Number of annotated genes in test set was 76. Number of annotated genes in ref set was 1487

10.1371/journal.pone.0070174.t007

###### Biological functions of genes surrounding SNPs from the two-locus interaction. Results from GeneTrail.

![](pone.0070174.t007){#pone-0070174-t007-7}

  Category                     rank            Subcategory             expected   observed   p-value(raw)   enrichment               Genes
  --------------------------- ------ -------------------------------- ---------- ---------- -------------- ------------ -------------------------------
  KEGG                          1               Amoebiasis               1.01        4          0.0178          up          ACTN1 CTSG GNA14 TGFB2
  KEGG                          2       T cell receptor signalling       1.04        4          0.0196          up           CBLB CD247 ICOS VAV3
  KEGG                          3         PPAR signaling pathway         0.66        3          0.0282          up             APOA5 CD36 FABP1
  KEGG                          5     Ubiquitin mediated proteolysis     1.34        4          0.0438          up           CBLB KLHL9 TCEB1 UBR5
  KEGG                          6        Primary immunodefciency         0.34        2          0.0441          up                 BTK ICOS
  KEGG                          7      Basal transcription factors       0.35        2          0.0465          up                GTF2B TAF7L
                                                                                                                        
  NIA humandiseasegene sets     1         Hyperlipoproteinemias          0.07        2          0.0017          up                APOA5 FABP1
  NIA humandiseasegene sets     2        Diabetes Mellitus Type 2        2.80        6          0.0493          up       APOA5 CCR5 CD36 CMA1 FABP1 TH

A total of 187 genes from the interaction analysis were put into the GeneTrail software.

Surrounding genes were defined by either Grail ([www.broadinstitute.org/mpg/grail/](http://www.broadinstitute.org/mpg/grail/)) or the Genome Browser (<http://genome.ucsc.edu/>). Gene families located in the same region were manually curated so that only one gene in each family remained in each region, based on a similar official gene symbol.

Size of test set: 186 (173 known). Number of known ref. IDs: 44829.

KEGG: number of annotated genes in test set: 52. Genes in reference set: 5405.

NIA human disease gene sets: number of annotated genes in test set: 20. Genes in reference set: 1487.

10.1371/journal.pone.0070174.t008

###### The top four networks generated by the Ingenuity IPA software (allowing only direct connections between proteins/genes).

![](pone.0070174.t008){#pone-0070174-t008-8}

  -------------------------------------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  1: Cell Morphology, Cellular Assembly and Organization, Hair and Skin Development and Function. Ingenuity Score: 155, 109 focus molecules.                                               ABT1,ACAP3,Ant,APLP2,APOA5,ARID1B,ASB6,ASPN,ATXN1,BASP1,BGN,BICD2,BIK,C1q,Cbp/p300,CCDC50,CCNL2,CD200,CD5L,CDK11A/CDK11B,CEP55,CHGA,COL22A1, collagen, **Collagen type I,Collagen type,IV**,Creb,CSF2RA,CXCL13,CYBA,CyclinA,CyclinE,DACH1,DCAF6,DCN,DDB1,DPP6,***DUSP10***,E2F3,E2f,EAPP,EFCAB7,ELOVL6, EPB41L2, [FABP1]{.ul},FCER1A,Fibrinogen,FOXD3,GGA1 (includesEG:106039),***[GLS]{.ul}***,GLTPD1,GRIA2,GSPT2,GSTT2/GSTT2B,GTF2B,HESX1,HIST1H3A (includes others),Histone h3,Histone h4,HMG20B,HoloRNApolymeraseII,HTATIP2,IGF2,Immunoglobulin,INS,Insulin,ITGA6,ITGA10,ITGB3BP,IVNS1ABP,KDM5A,KLF12,**LAMA2,Lamin b, Laminin1,Laminin**,LBR (includes EG:368360),LIG4,LSAMP,LUM,**MMP17,Mmp,MMP23B**,MNAT1,MTTP,MVD,N-cor,NAP1L3,NBPF11, (includes others),NCOA5,**NFkB(complex),**NFRKB,NTS,PAX5,PBX3,PCBD2, PKIB,POU2F1, POU3F2,PPARA,PPM1F,PRL,PRMT3,PRMT8,PRNP,PTGES,PVR,pyruvate kinase, Rb,RBM8A,***[RGS1]{.ul}***,RNA polymeraseII,RNF126,SLC25A6,SMC2,SRSF7,SYT8,TAF7L,TCEB1,TEAD4, **Tgf beta,TGFB2**,TGFBRAP1,THBS2,thymidine, kinase,thyroid hormonereceptor,TNFRSF4,TRHDE,TSPO,TXNIP,**Ubiquitin,**UBR5,Vegf,VEGFA,VIM,VPREB1,VPS37C,WT1,ZRANB1
  2: Cell Signaling, Molecular Transport, Vitamin and Mineral Metabolism. Ingenuity score: 97, 86 focus molecules.                              14-3-3,Actin,ADRA1B,ADRA1D,ADRBK2,AGT,AKAP13,Akt,alcohol group acceptor phosphotransferase, ***ACTN1***, Alpha tubulin,Angiotensin IIreceptor type 1,Ap1, ARHGAP5, ARHGEF18,BCL2,BCL2L11,BTK,Calmodulin,CaMKII,CARD11,caspase,CBLB,***CCR5*** **,**CD3,CD6,CD36,CD38,CD40,***CD247*** **,**chemokine,**CTSG**,CX3CR1,DARC, DISC1,DMD,DVL1,Dynamin, Dynein,dystroglycan,EGF (includesEG:13645),EPB41L3,EPHA7,ERK,ERK1/2,estrogen receptor,F Actin,FCRL4,FHL2,**Focal adhesion kinase**,Gprotein,Gap,GLRX3,**GNA12**,GNB1,Gpcr, GPR20,GPR27,GPR33,GPR45,GPR111,GPR115,GPR149,GPR161,growthfactor receptor,**GZMB**,Hsp70,Hsp90,HTR2C, ***ICOS***,Iga,INADL,[INSR]{.ul},JAK,Jnk,KLF10,LIN7A,LPHN2,LTF,MAPK1,Mapk,**MHC Class I (complex),** ***MHC Class II (complex***),MITF,Mlc,MRC1 (includes EG:100286774), MYT1L,NADK,NCK2,Nfat(family),NMDAReceptor,O3FAR1,OR51E2, ***P38 MAPK***, p85 (pik3r), Pak,PAWR,PDCD6IP,[PDK1]{.ul},PDPN (includes EG:10630),PI3K(complex),PI3K p85,Pkc(s),PKN2,PLC gamma,POMC,PP2A,**PPP3CA,PRKCH,PRKCQ,PRKCZ**,PTGDR2,**PTK2**(includes EG:14083),Rac,Ras,RASSF5,Rxr,SGCG, SMARCA2,SOD1,Spectrin,STAM,***STAT1*** *,*STAT,STAT5a/b,TAB1,TAS1R3,TCR,TH,THRB,TIAM1,TIMM8A,TNNT3,Troponin t, TUB,Tubulin, UTRN,VAV3,VAV,VN1R5
  3: Cellular Assembly and Organization, Cellular Function and Maintenance, Developmental Disorder. Ingenuity score: 77, 69 focus molecules.                                                                                            ABCG1,ABTB2,ACAD9,ACAD10,ACADSB,ADI1 (includesEG:104923),AGPAT2,AGPAT3,AGPAT4,AGPAT5,AGPAT6,ALDH18A1,ARL6,ATL2,B9D1,BAIAP2L1,BCL2L13, BRP44,C10orf35,C10orf88,CAMLG,CC2D2A,CCBL2,CCNI,CDH18,CDK5RAP2,CHIC2,CNTNAP2,CPSF3L,CRYL1,CTNNA2,DDX46,DMXL1,DOCK4,DSE,EBNA1BP2,ELMO2,ELMO3,ERGIC1,ERGIC2,ERGIC3,FAM125A,FAM125B,FAM175B,FBXO8,GEMIN6,GEMIN8,GLA,GNL1,HAUS2,HAUS3,HAUS5,HAUS7,HAUS8,HCN1,HCN2,HERC3,HERC4,HERC6,HFE,HNRNPH2,HNRPLL,IFT20,IFT52,IFT57,IFT88,IL13RA1,IL13RA2,INTS2,INTS9,***LPP*** *,*LSG1,MAD2L1BP,MAGEH1,MAOA,MCAT,MICAL3,MKS1 (includes EG:287612),MOAP1,MRPL23,MRPL20 (includes EG:39477),MRPL3 (includes EG:11222),MRPL40(includesEG:18100),MRPS21,MTAP,MYLIP,MYO1F,NDUFAB1, OSTF1,OXA1L, PALM,PCMTD1,PHKA1,PHRF1, PIGQ,PIGY,PPAP2B,PRAME,PTPN14,PYGB,REEP5,RIC3,RNF122,RNF166,RTN3,SARS2,SCYL3,SEC24A,SEC24B, SEMA5A, SERINC1, SGSH,SHPRH,SIL1(includesEG:100334837),SIPA1L2,SIPA1L3,SLC17A2, SLC23A2,SMEK2,SMOX,SSU72,STK19,TBC1D15,TCTN2,TFAP4,TFR2,TGM3,THAP5, TIPRL, TOP3B,TRIM17,TRIM44,TUBG2,*UBC*,USP44,VEZT,VPS37A,ZDHHC8,ZMIZ1,ZNF259
  4: Post-Translational Modification, Carbohydrate Metabolism, Lipid Metabolism. Ingenuity score: 74, 67 focus molecules.                                                                                                                          AGXT2L1,AHCYL2,ANGEL1,ANKRD17,ANKRD34A,ARMC9,ASXL1,ASXL2,AURKAIP1,B3GALT6,BAP1,BTN3A2,C15orf41,C1orf112,C1orf198,C2CD2,C9orf106,CCDC86,CCNDBP1,CCPG1,CENPP,COX20 (includesEG:116228),CTU2,CXXC4,DAK,DENND3,DHRS3,DLST,EFR3B,ELF2,ENDOV,FBXL4,FIS1 (includes EG:288584), FTO,GDAP1,HAT1,HSPA2,IER3IP1,IFIH1,IMP3,INPP5A,INPP5B,INPP5E,INPP5K,IPO4,IPPK,KANK4,KCNK10,KDM1B,KHNYN,LMBR1,MB21D2,MCF2L,MED20,METTL10,MRPL15 (includes EG:27395),MRPS18A,MRPS9 (includesEG:301371),MTCH1,MTMR8,MTMR9,PABPC5,PAN2,PITRM1,PMPCA,POLR3GL,PPM1G,PRDM10,PRPSAP2,PRUNE2, PSMB10, PSTK,PUSL1,PXDNL,RCN3,RPL28,SAR1B,SCAF4,SCNN1D,SDR39U1,SEC13,SEC16A,SEC16B,SEC23A,SIRT6,SLC35C2,SLC39A10,SLC45A4,SLC6A3,SYF2 (includes EG:170933),SYNGR1,SYNJ2,TAPT1,TMEM70, TMEM132A,TPTE/TPTE2,TRMT5,TSPAN9,TTYH2,TTYH3,TXNDC15,*UBC*,UBE2O,UCHL1,UCHL3,USP2,USP3,USP5,USP6,USP10,USP13,USP16,USP18,USP21,USP24,USP25,USP28,USP30,USP32,USP33,USP34,USP35,USP36,USP37,USP38,USP40,USP42,USP44,USP45,USP47,USP48,USP53,USP54,USP27X,USP9Y,XXYLT1,ZC3H13,ZNF131,ZNF334,ZNF608
  -------------------------------------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

The results of the network analysis included our genome-wide significant finding (*DUSP10*) within the top scoring network. P38 MAPK which interacts with DUSP10 is included in the second top network. Also the MHC class II complex is part of the second network. Genes within ours (P38 MAPK and DUSP10) and previously identified genome-wide significant regions are marked in italic, bold text. Only bold text show genes involved in amoebiasis. Underlined genes showed differences in our gene expression analysis ([Table 9](#pone-0070174-t009){ref-type="table"}).

Rank; Top functions; Ingenuity score; Number of focus molecules; Molecules in Network.

Gene Expression {#s2e}
---------------

Out of the 34 selected target genes, three were from the top associated SNPs (*DUSP10, SVIL* and *PPP1R12B*) and the remaining were genes identified from the two-locus and pathway analysis. Eight genes showed significant up- or down-regulation after correction for multiple testing using Bonferroni correction ([Fig. 4](#pone-0070174-g004){ref-type="fig"}). For the top associated genes, several transcript variants were tested ([Table 9](#pone-0070174-t009){ref-type="table"}). For the *PPP1R12B* gene, Isoform c and d (transcript variants NM032103.2 and NM032104.2) also known as the small subunit (sm-M20) of myosin light chain phosphatase, show significant up-regulation in patients with CD autoimmunity compared to control patients. An additional ten genes showed nominally significant differences in expression ([Table 9](#pone-0070174-t009){ref-type="table"}).

![Gene expression results.\
Fold change on the y-axis is plotted for each individual in the two groups, 46 CD cases and 52 control patients. Each circle in the graph represents an individual. The mean expression value of the control group is set to 1.](pone.0070174.g004){#pone-0070174-g004}

10.1371/journal.pone.0070174.t009

###### Results from gene expression analysis of 34 candidate genes.

![](pone.0070174.t009){#pone-0070174-t009-9}

  Gene symbol                                Assay id                                             Gene                                               Fold Change         p-value   p-value corr.[b](#nt140){ref-type="table-fn"}   Selection criteria  
  --------------------------------------- --------------- ------------------------------------------------------------------------------------ ------------------------ --------- ----------------------------------------------- -------------------- ----------------------------
  ADCY9[a](#nt138){ref-type="table-fn"}    Hs00181599_m1                                  adenylate cyclase 9                                            1.58             DOWN                       7.55E-06                           2.87E-04                two-locus
  APPL2[a](#nt138){ref-type="table-fn"}    Hs00216855_m1   adaptor protein, phosphotyrosine interaction, PH domain and leucine zipper cont. 2            1.51             DOWN                       2.15E-05                           8.19E-04                two-locus
  GLS                                      Hs00248163_m1                                      glutaminase                                                1.48             DOWN                       2.20E-05                           8.38E-04        two-locus/IPA/top previous
  PRR5L                                    Hs01029928_m1                                  proline rich 5 like                                            1.46              UP                        4.99E-05                           1.90E-03                upreg TNFa
  INSR                                     Hs00961554_m1                                    insulin receptor                                             1.41             DOWN                       8.39E-05                           3.19E-03                two-locus
  KIF13A                                   Hs00223154_m1                               kinesin family member 13A                                         1.22             DOWN                       1.76E-04                           6.68E-03                two-locus
  PPP1R12B                                 Hs00364073_m1               protein phosphatase 1, regulatory (inhibitor) subunit 12B                         1.44              UP                        2.05E-04                           7.78E-03                   top
  PPP1R12B                                 Hs00364078_m1               protein phosphatase 1, regulatory (inhibitor) subunit 12B                         1.15              UP                        7.75E-04                            0.029                     top
  PDK1                                     Hs01561850_m1                        pyruvate dehydrogenase kinase, isozyme 1                                 1.30              UP                        9.42E-04                            0.036                     IPA
  FABP1                                    Hs00155026_m1                          fatty acid binding protein 1, liver                                    1.38             DOWN                       1.63E-03                             0.06                  two-locus
  RGS2[a](#nt138){ref-type="table-fn"}     Hs01009070_g1                           regulator of G-protein signaling 2                                    1.26             DOWN                       2.32E-03                             0.09               IPA/top previous
  DPP10                                    Hs00397766_m1                                dipeptidyl-peptidase 10                                          1.75             DOWN                       4.22E-03                             0.16                  two-locus
  IKBKE                                    Hs01063858_m1     inhibitor of kappa light polypeptide gene enhancer in B-cells, kinase epsilon               1.18              UP                          0.014                              0.52           two-locus/IPA/genetrail
  UNC5C                                    Hs00186620_m1                              unc-5 homolog C (C. elegans)                                       1.17             DOWN                         0.015                              0.59                     IPA
  ARID1B                                   Hs00368175_m1                             AT rich interactive domain 1B                                       1.13             DOWN                         0.017                              0.63                  two-locus
  PKN2                                     Hs00178944_m1                                   protein kinase N2                                             1.14             DOWN                         0.024                              0.91                  two-locus
  ITPK1                                    Hs00356546_m1                         inositol 1,3,4-triphosphate 5/6 kinase                                  1.13             DOWN                         0.026                              0.99                  two-locus
  RGS1                                     Hs00175260_m1                           regulator of G-protein signaling 1                                    1.41              UP                          0.026                              1.00               IPA/top previous
  SVIL                                     Hs00931734_m1                                      supervillin                                                1.34             DOWN                         0.035                              1.00                     top
  PPP1R12B                                 Hs00981888_m1               protein phosphatase 1, regulatory (inhibitor) subunit 12B                         1.08             DOWN                         0.053                              1.00                     top
  APPL1                                    Hs00989616_m1   adaptor protein, phosphotyrosine interaction, PH domain and leucine zipper cont. 1            1.10             DOWN                         0.055                              1.00           two-locus/IPA/genetrail
  MTTP                                     Hs00165177_m1                        microsomal triglyceride transfer protein                                 1.21             DOWN                         0.100                              1.00                     IPA
  COQ3                                     Hs00213616_m1                 coenzyme Q3 homolog, methyltransferase (S. cerevisiae)                          1.23             DOWN                         0.196                              1.00                  two-locus
  SVIL                                     Hs00931014_m1                                      supervillin                                                1.18             DOWN                         0.221                              1.00                     top
  CD200                                    Hs01033303_m1                                     CD200 molecule                                              1.09              UP                          0.368                              1.00                     IPA
  MAGED1                                   Hs00986269_m1                              melanoma antigen family D, 1                                       1.04             DOWN                         0.512                              1.00                IPA/genetrail
  FOXD3                                    Hs00255287_s1                                    forkhead box D3                                              1.13              UP                          0.547                              1.00                  two-locus
  ITPK1-AS1                                Hs01053867_s1                   inositol 1,3,4-triphosphate 5/6 kinase Associated                             1.10             DOWN                         0.548                              1.00                  two-locus
  LPP                                      Hs00194400_m1                                Lipoma-preferred partner                                         1.07             DOWN                         0.634                              1.00            two-locus/top previous
  RGS5                                     Hs00186212_m1                           regulator of G-protein signaling 5                                    1.04             DOWN                         0.699                              1.00                     IPA
  DUSP10                                   Hs00200527_m1                            dual specificity phosphatase 10                                      1.12              UP                          0.704                              1.00                     top
  FSCB                                     Hs03044256_s1                          fibrous sheath CABYR binding protein                                   1.12             DOWN                         0.735                              1.00                  two-locus
  CCR3                                     Hs00266213_s1                            chemokine (C-C motif) receptor 3                                     1.05              UP                          0.737                              1.00                  two-locus
  TIPRL                                    Hs00295580_m1              TIP41, TOR signaling pathway regulator-like (S. cerevisiae)                        1.01             DOWN                         0.752                              1.00                  genetrail
  KHDRBS2                                  Hs01061150_m1          KH domain containing, RNA binding, signal transduction associated 2                    1.06              UP                          0.840                              1.00                  two-locus
  GTF2B                                    Hs00976258_m1                            general transcription factor IIB                                     1.03              UP                          0.888                              1.00                IPA/genetrail
  ACTN1                                    Hs00998100_m1                                    actinin, alpha 1                                             1.01             DOWN                         0.914                              1.00                  two-locus
  DUSP10                                   Hs04189838_m1                            dual specificity phosphatase 10                             No expression detected     top                                                                         

Expression (e.g. mRNA levels) of these genes was either up- or down-regulated in small intestinal biopsies from CD cases compared with control patients. Effect direction is presented for cases with control group as a reference. The selection column indicates if the gene was selected due to its presence in two-locus or pathway analyses. "Top" indicates top SNP in the present GWAS and "top previous" indicates that it was present in the GWAS by Dubois et al.

All the gene assays (primers and probes) were predesigned and ordered from Life technologies (CA, USA).

Reference genes tested were: ACTB (Hs00357333_g1), B2M (Hs99999907_m1), EPCAM (Hs00158980_m1), GUSB (Hs99999908_m1), HPRT1 (Hs99999909_m1), MUC1 (Hs00159357_m1), PGK1 (Hs99999906_m1). For the results a combined value of ACTB, EPCAM, and PGK1 showed to be optimal when analysed by GeNorm and were selected as reference.

Gene not included in the gene list used for pathway analyses due to recombination between associated SNP and gene promotor: rs10861406.

(APPL2), rs882820 (ADCY9). However, possible regulatory site could be close to associated SNP and influence gene expression.

P-values corrected using Bonferroni correction.

Non-parametric Linkage (NPL) {#s2f}
----------------------------

The strongest linkage outside of HLA was detected in chromosome regions 5q23.2-q33.1, and 1q32.1. In total, thirteen regions with an NPL point wise p-value below 0.01 were detected ([Fig. 5](#pone-0070174-g005){ref-type="fig"} and [Table 10](#pone-0070174-t010){ref-type="table"}). In our previous linkage-scan, using almost the same set of families, we detected only one region (11q23-25) with a point wise p-value below 0.01 [@pone.0070174-Naluai2]. The reason for the improved results is mainly the almost perfect information content achieved by a dense set of highly successful SNP markers compared to a relatively sparse set of less successful microsatellite markers. Also in the NPL analysis, the *PPP1R12B* gene was located in one of the top regions (1q32.1).

![NPL results.\
Non-Parametric Linkage score displayed as --log10(p-value) on the y-axis and chromosome 1--22 and X on the x-axis.](pone.0070174.g005){#pone-0070174-g005}

10.1371/journal.pone.0070174.t010

###### Non Parametric Linkage (NPL) results.

![](pone.0070174.t010){#pone-0070174-t010-10}

  chr                                  from(Mb)   to(Mb)   max NPL   p-value
  ----------------------------------- ---------- -------- --------- ----------
  6[a](#nt144){ref-type="table-fn"}      12,5      52,6     5,42     3,03E-08
  5                                     124,5     149,3     3,33     4,36E-04
  1                                     200,2     231,8     3,12     9,20E-04
  11                                    122,2     130,2     2,95     1,59E-03
  9                                      30,3      34,7     2,82     2,40E-03
  4                                      96,5     111,3     2,81     2,46E-03
  3                                     104,7     108,6     2,70     3,49E-03
  14                                     85,7      86,4     2,57     5,16E-03
  6                                     160,4     161,0     2,54     5,50E-03
  11                                     77,6      78,4     2,48     6,64E-03
  18                                     55,0      55,1     2,45     7,20E-03
  1                                      29,7      29,9     2,42     7,87E-03
  2                                     127,0     127,1     2,41     8,00E-03
  2                                     106,3     106,4     2,37     8,89E-03

Regions showing significant linkage (the HLA region only) and putative linkage (nominal p\<0.01. Regions in the table are defined as the Megabase (Mb) interval showing a nominal p\<0.01. Neighbouring regions were merged if \<15 Mb pairwise distance.

Max NPL -- the maximum Z score across the region between the positions 'from' and 'to'.

p-value -- the p-value for the max NPL score.

 = The HLA region.

Discussion {#s3}
==========

This study confirmed some previous GWAS findings and in addition, it established a new genome-wide significant region containing the *DUSP10* gene. The top markers, rs12144971 and rs4240931 showed a substantial effect size in the HLA low-risk group with a transmitted versus non-transmitted allele ratio of 3.11 ([Table 2](#pone-0070174-t002){ref-type="table"}).

DUSP10, TNF-α and Tissue Transglutaminase (TGM2) {#s3a}
------------------------------------------------

The protein product of *DUSP10* preferentially binds to the stress-activated p38 MAPK (mitogen-activated protein kinase) and plays an important role in regulating chemokine induction after infection by various pathogens [@pone.0070174-Taxman1], and in coordinating MAPK activity in response to oxidative stress [@pone.0070174-Teng1]. In previous studies, both p38 MAPK and DUSP10 have been shown to activate TNF-α [@pone.0070174-Bayardo1], [@pone.0070174-Luo1], of which one also demonstrates that TNF-α up-regulates *TGM2* (the gene encoding the main autoantigen in CD [@pone.0070174-Dieterich1]) in intestinal mucosa from untreated CD patients [@pone.0070174-Bayardo1]. Whether this up-regulation of *TGM2* is of importance for the immune response leading to formation of IgA-tTG and IgG-tTG autoantibodies, the serological markers for CD is still unresolved.

Pathway Analyses {#s3b}
----------------

In order to discover possible functional connections between *DUSP10* and other genes, we analyzed genes surrounding the top 603 markers. A total of 845 genes were used in the analysis. Ingenuity pathway analysis (IPA) included *DUSP10* within the most significant network. Also part of this network were *GLS* and *RGS1,* two genes previously identified within significant GWAS loci [@pone.0070174-Dubois1], as well as the *insulin (INS)* gene, and the immune regulatory nuclear factor kappa B (NF-Κb) complex ([Fig. 3](#pone-0070174-g003){ref-type="fig"} and [Table 8](#pone-0070174-t008){ref-type="table"}). The second top network included the MHC complex (HLA) and also several genes within already identified GWAS loci: *ACTN1, CD247, CCR5, ICOS* and *STAT1* [@pone.0070174-Dubois1]. In addition, both IPA and GeneTrail [@pone.0070174-Backes1] identified T2D genes as the most significantly overrepresented gene cluster after correction for multiple testing ([Table 5](#pone-0070174-t005){ref-type="table"} and [6](#pone-0070174-t006){ref-type="table"}). Among this set of genes surrounding the 603 markers, many genes belonged to growth and nutrient signaling pathways, for example, *INS*, *INSR*, *EGF*, *POMC*, *TIPRL and PRR5L*. There were also related genes directly involved in energy metabolism; *PDK1, COX7C, COQ3* and *GLS*.

Overlapping Results with Other GWAS Findings {#s3c}
--------------------------------------------

Surprisingly, four out of six top loci identified by a GWAS for anorexia nervosa [@pone.0070174-Wang1] and two out of three loci involved in plasma glucose levels in type 1 diabetic patients [@pone.0070174-Paterson1] were among our 603 and 35 best SNP markers respectively. One of the genes in anorexia, namely *AKAP6, is also associated to* fasting insulin-related traits as well as the autoimmune disease Ankylosing spondylitis [@pone.0070174-Lin1]. Of the 40 identified regions in CD, seven regions overlap with our 603 SNP list (*LPP, STAT4/GLS, RGS1, CCR1/CCR3, PUS10, ICOS/CTLA4* and *CD247*). Out of the 69 regions reported in the GWAS catalog for type 1 diabetes, eight overlap with the regions reported in this study and out of those eight, *CTLA4/ICOS* also overlap with the previously reported CD associations.

We compared minor allele frequencies between the previous CD GWAS by Dubois et al. and our GWAS. In their top 42 associations, there was no SNP below a minor allele frequency of 0.08. In our top 42 associations, we identified five SNPs with a minor allele frequency below 0.06. This observation could just be a chance finding or perhaps an indication that rare variants are easier to discover using families. We also identified a relatively rare variant in the LPP gene region (rs17283813), with a minor allele frequency of 0.075. This SNP was not at all significant in the GWAS by Dubois et al. ([Table S1](#pone.0070174.s001){ref-type="supplementary-material"}).

Neither was there an association with the *DUSP10* region in the GWAS by Dubois and co-workers. The associated markers in the *DUSP10* region in our GWAS have a minor allele frequency around 0.5 and are hence very common in the population. It is difficult to say if this is a population specific effect or if *DUSP10* could be detected in an HLA stratified population from another ethnicity. Interestingly, the *DUSP10* region has also been identified as a risk factor for colon cancer by a meta-analysis of three GWAS from the UK. This is an indication that colon cancer and CD could share genetic risk factors.

Key Metabolic Regulators as well as the Top Associated gene PPP1R12B were Differently Expressed in CD Cases Compared to Controls {#s3d}
--------------------------------------------------------------------------------------------------------------------------------

Another important finding was the difference between cases and controls and their gene expression patterns in the small intestine. Eight of the 34 candidate genes selected for quantitative measurements of gene expression, including *PPP1R12B, PDK1*, *GLS*, *PRR5L* and the *INSR*, showed significant up or down regulation of mRNA levels in cases compared to controls ([Fig. 4](#pone-0070174-g004){ref-type="fig"}). This could very well be a consequence of an ongoing inflammation or possibly also indicate an underlying metabolic difference. Glutamine is converted to glutamate by the enzyme glutaminase (GLS). In turn, glutamate can be converted to proline and subsequently catabolized by the enzyme proline dehydrogenase (PRODH) resulting in the production of reactive oxygen species and apoptosis [@pone.0070174-Liu1]. In the present study, we show that the expression of *GLS* is down-regulated and *PDK1* is up-regulated in cases. Interestingly, a previous study has shown that cell lines with a known familiar mutation for amyotrophic lateral sclerosis (ALS) have the same expression pattern, with up-regulated *PDK1* and down-regulated *GLS,* as compared to the wild-type cell line [@pone.0070174-DAlessandro1]. *PRR5L* (also called Protor-2) belong to the TOR signaling pathway. Our results show an up-regulated *PRR5L* expression in cases ([Fig. 4](#pone-0070174-g004){ref-type="fig"}). Like DUSP10, the protein product from *PRR5L* has been shown to stimulate an increased TNF-α expression [@pone.0070174-Holmes1].

Another gene, connected to the MAPK pathway and which was identified both by our two-locus interaction analysis and in significant biological functions implied by IPA, was the *APPL1* gene. *APPL1* is a binding partner of the protein kinase Akt2 and a key regulator of insulin signaling [@pone.0070174-Saito1]. It takes part in adiponectin signaling to stimulate activity of p38 MAPK in muscle cells [@pone.0070174-Xin1] and is a critical regulator of the crosstalk between adiponectin signaling and insulin signaling pathways [@pone.0070174-Mao1]. We could detect expression of both *APPL1* and *APPL2* in small intestinal biopsies and a significantly lower expression of *APPL2* was detected in the CD autoimmunity cases as compared to controls ([Fig. 4](#pone-0070174-g004){ref-type="fig"}). Lower expression of *APPL2* levels lead to enhanced adiponectin stimulated glucose uptake and fatty acid oxidation [@pone.0070174-Wang2]. A SNP (rs10861406) included in the top 603 list was located upstream of the *APPL2* gene, however the promotor of this gene was on the opposite side of a recombination hotspot and therefore not included in the gene list for pathway analyses.

The most significant finding from our non-stratified linkage GWAS analysis was the association with the *PPP1R12B* gene region. *PPP1R12B* is involved in smooth muscle contractibility and mediates binding to myosin [@pone.0070174-Ito1]. Myosin light chain phosphatase from smooth muscle consists of a catalytic subunit (PP1c) and two non-catalytic subunits, M130 and M20. The two non-catalytic subunits are both encoded by the *PPP1R12B* gene. The M130 transcript was not differentially expressed between CD autoimmunity and control patients while the small subunit "M20" showed a significantly higher expression in patients with CD autoimmunity. (*PPP1R12B*\_22 in [Fig. 4](#pone-0070174-g004){ref-type="fig"}) Several other genes located close to top markers such as the *PPP3CA, ACTN1, MYO1B, MYO5A, MAPK1, PRKCH, PRKCQ, PRKACB, PRR5L and NTS genes,* are connected to smooth muscle when examining their function by using *KEGG* [@pone.0070174-Goto1] and Gene Ontology [@pone.0070174-Ashburner1].

The second most significant region in the HLA-stratified analysis after *DUSP10* contains the *SVIL* gene. The product of this gene has been suggested to bind LPP [@pone.0070174-Takizawa1]. In our two-locus interaction analysis, the *LPP* locus and a locus containing *KIF13A* was one of the 101 interaction pairs. *KIF13A* is a motor protein, which shuttles vesicles containing AP-1 and the mannnose-6-phosphate receptor [@pone.0070174-Nakagawa1]. *KIF13A* was significantly down-regulated in intestinal biopsies from CD patients in our gene expression analysis ([Fig. 4](#pone-0070174-g004){ref-type="fig"}). *SVIL* is associated with cell-focal adhesions (substrate contacts), which are important for rapidly moving cells such as for example immune cells but also for motility and polarity of intestinal epithelial cells. *SVIL* mRNA was down-regulated in our gene expression analysis, however, not significant after correction for multiple testing.

Proline and Glutamine Metabolism - Part of a "Danger Signal" {#s3e}
------------------------------------------------------------

Amoebiasis was one of the nominally significant pathways in the GeneTrail analysis of genes surrounding the two-locus interaction SNPs ([Table 7](#pone-0070174-t007){ref-type="table"}). Several of these genes were also present together with *DUSP10* and the MHC class II genes in the two most significant IPA generated networks (marked in bold text in [Table 8](#pone-0070174-t008){ref-type="table"}). Another gene present in these networks was the gene encoding for the immune molecule CD40 (associated SNP rs6065961, [Table S1](#pone.0070174.s001){ref-type="supplementary-material"}). CD40 has been shown to regulate immune responses to another parasite, Leishmania Major, by shared signaling through p38 MAPK and ERK1/2 [@pone.0070174-Srivastava1]. CD40 also regulates DUSP expression and activity, which in turn contribute to anti-leishmanial functions [@pone.0070174-Srivastava1]. It has been suggested that Leishmania Major inhibits CD40-triggered p38 MAPK signaling as part of an immune evasion strategy [@pone.0070174-Awasthi1].

Another overrepresented category from GeneTrail was the extracellular matrix (ECM) ([Table 6](#pone-0070174-t006){ref-type="table"}). Also, in the two most significant Ingenuity networks from the 603 marker analyses, ECM molecules and matrix metalloproteinases (MMPs) were included ([Table 8](#pone-0070174-t008){ref-type="table"}). The ECM represents a major barrier to parasites like amoebas and leishmania. Parasites produce a wide variety of proteases to break down the ECM in order to access essential nutrients and invade host tissue [@pone.0070174-PinaVazquez1]. A different situation when the ECM is degraded is during nutrient deprivation. In this way the ECM can provide energy for starving host cells. Just like gluten, the ECM has an unusually high proline content. MMPs are enzymes, which break down ECM making proline readily available as a nutritional source. Pandhare and co-workers have shown that energy or nutrient stress activates MMPs as well as the degradation of proline and furthermore demonstrated that, as the levels of glucose decreased to 1 mM and lower in the medium, intracellular proline increased almost 2-fold [@pone.0070174-Pandhare1]. If gluten lingering in the intestine conveys a signal of ECM degradation (due to increased proline levels), several other mechanisms will most likely signal that there is food available at the same time (salivary secretion as one example is shown in [Table 6](#pone-0070174-t006){ref-type="table"}). In this case, the immune system will rule out starvation as a possibility and the only other sensible option would be to search for an invasive intruder breaking down the ECM. The autoantigen in CD, TGM2, counteracts proteolysis and degradation of ECM by crosslinking ECM proteins [@pone.0070174-Mangala1]. If DUSP10 and PRRL5 up-regulate TNF-α and subsequently TGM2 [@pone.0070174-Bayardo1], [@pone.0070174-Luo1], [@pone.0070174-Holmes1], in CD, the purpose may very well be for TGM2 to help prevent an apparent or illusory pathogenic invasion. It has also been shown that down-regulation of SVIL protects against ECM invasion by pathogens [@pone.0070174-Crowley1]. In our gene expression analysis SVIL was nominally significantly down-regulated in cases ([Table 9](#pone-0070174-t009){ref-type="table"}).

When the body "senses" a pathogen disturbing energy balance or breaking down ECM, but there are no pathogenic antigens present, maybe there could be a risk that "self" antigens become our immune systems futile attempt to rid the perceived pathogen. In HLA-DQA1\*02/05 and HLA-DQB1\*02 carriers, peptides derived from TGM2 could constitute such "self" antigens. It is possible that individuals carrying other HLA molecules still respond to this "phantom pathogen" and that under these circumstances, various other antigens present in the intestine at the time could become triggers of other autoimmune diseases. If the expression or presence of an autoantigen, like TGM2, was stimulated by the disturbed proline/glutamine homeostasis, it can explain why symptoms in CD also disappear by withdrawal of gluten.

Conclusion {#s3f}
----------

At least four major functional components together with gluten, all seem to play a role in forming an individual's risk for CD:

1.  polarity and epithelial cell functionality, e.g. nutrient/vesicle transport, proliferation and apoptosis, important for cell migration from the crypt to the shedding (apoptosis) at the apical villi.

2.  intestinal smooth muscle, which is important for the movement of the bowel as well as the villi.

3.  growth and energy homeostasis, which includes proline and glutamine metabolism, and finally

4.  the innate and adaptive immune system.

A slight dysfunction combining these categories together with gluten consumption would result in a metabolic imbalance which in turn could convey enough stress or "danger signal", to trigger the immunological process and tissue destruction. A schematic illustration showing a rough outline of a possible disease model is presented in [Figure 6](#pone-0070174-g006){ref-type="fig"}.

![Proposed disease model.\
Illustrating a possible scenario for disease development. Genetic variation contributing susceptibility to disease can be found in at least four, somewhat overlapping, biological functions. The result is an "overload" or imbalance of proline vs glutamine. Due to the abundance of proline within the extracellular matrix (ECM) as well as in gluten, the proline from gluten is interpreted as degradation of ECM. When the body is not starving, the ECM is normally not degraded, unless there is a pathogen attempting to break through this barrier. The immune system mounts an attack against an invasive "phantom pathogen" which is believed to degrade the ECM. When proline is catabolized, reactive oxygen species (ROS) are released. In order to start re-building and crosslinking ECM molecules, Tissue transglutaminase (*TGM2*) expression is up-regulated by TNFα which in turn is stimulated by DUSP10 and Protor-2 (PRR5L). This rebuilding of the ECM counteracts the degradation by the imagined pathogen. However, the phantom pathogen remains and the adaptive immunity is brought in. Searching for antigens, it finds an abundance of TGM2 beside the ECM and forms antibodies against its own soldier. Some susceptibility genes can be found in the center of this model and some can be found within the spiral. Genes like *HLADQ* and other genes from the adaptive immunity are likely to be found in the spiral.](pone.0070174.g006){#pone-0070174-g006}

In this study, we identified *DUSP10* to be significantly associated with celiac disease. We also identified mechanisms, which we believe influence the risk of developing disease. Our data points towards genes that are involved in cancer as well as metabolic and cardiovascular diseases. Besides understanding how they work in celiac disease, our findings could also have consequences for these other common diseases.

Whole genome analysis allows for discovering completely unknown mechanisms behind disease. Even if the discovered genes and gene variants won't be able to predict who will develop disease in the future, they can be used to identify the underlying molecular pathways that influence disease. These molecular pathways would then be valuable targets for drug intervention. Our data provides new insights and hypotheses to the research field of CD and autoimmunity. However, the functional variants behind associations as well as mechanisms causing differences in gene expression and if and how these are relevant for disease, remains to be identified.

Materials and Methods {#s4}
=====================

Ethics Statement {#s4a}
----------------

The regional ethics board in Gothenburg approved this study and participants in the study gave written informed consent after being fully informed about the aim of the study. For all children in the study, parental written consent was obtained.

Study Population {#s4b}
----------------

A total of 106 families with multiple affected individuals, mostly nuclear families with an affected sib pair (ASP) were collected from Sweden and Norway. There were 403 subjects and 97 families with DNA to complete the analysis. A total of 226 of the family members had CD, including 20 parents. The makeup and selection process regarding the families has been described previously in detail [@pone.0070174-Gudjonsdottir1].

Small-intestinal biopsies, for the gene expression analysis, were collected at four pediatric clinics in Sweden: Skåne University Hospital in Malmö, Sach's Childrens' Hospital and Karolinska University Hospital in Stockholm and Sahlgrenska University Hospital in Gothenburg. For gene expression calculations, we decided to use case-control status based on anti-tTG IgA and IgG antibody levels in plasma using the Radio-Binding Assay (RBA) [@pone.0070174-Grubin1], [@pone.0070174-Kjelleras1]. Patients being both tTG IgA and IgG positive (\>4 U/ml) were included as cases (we use the term "CD autoimmunity" for these cases [@pone.0070174-Norris1]) and all other individuals were included as disease controls. The LPP gene was run in a first set of 42 cases (30 females, 12 males) and 38 control patients (21 females, 17 males). Cases and controls had a mean age of 7.3 and 11.1 years respectively. The remaining genes were run in a second set of 46 cases (25 females, 21 males) and 52 control patients (27 females, 25 males) with a mean age of 7.4 years for cases and 11.8 years for control patients at the time the biopsy was taken.

Gene Expression Analysis {#s4c}
------------------------

We performed quantitative gene expression analysis using duodenal biopsies from CD autoimmunity patients and control patients. Biopsies were immediately put in RNAlater solution (Life Technologies, CA, USA). Total RNA was extracted using the miRNeasy Mini Kit (QIAGEN, Germany). RNA was converted to cDNA and quantitative PCR was run using TaqMan chemistry and the ABI7900 SDS instrument (Life Technologies, CA, USA). Seven control genes were evaluated using GeNorm [@pone.0070174-Vandesompele1] (ACTB (Hs00357333_g1), B2M (Hs99999907_m1), EPCAM (Hs00158980_m1), GUSB (Hs99999908_m1), HPRT1 (Hs99999909_m1), MUC1 (Hs00159357_m1), PGK1 (Hs99999906_m1)) and the geometrical mean of *ACTB, EPCAM*, and *PGK1* were selected as reference for the relative quantification analysis (Delta-Delta Ct method). A total of 34 expressed genes located close to some of the most significantly associated SNPs were evaluated ([Table 9](#pone-0070174-t009){ref-type="table"}). The top associated genes from our Linkage GWAS (*DUSP10, SVIL, PPP1R12B*) were selected as well as several genes from the two-locus interaction analysis and pathway analyses including *LPP* which is the top associated from the GWAS by Dubois et al. Also the RGS genes (*RGS1, 2 and 5*) and *GLS* show genome-wide association in the study by Dubois et al and are also present in our two-locus and pathway analyses.

Genotyping and Imputation {#s4d}
-------------------------

Samples were genotyped using two different SNP arrays, 211 samples with Human Omni Express and 192 samples with Human 660W-Quad (Illumina Inc, CA, USA). A total of 308,246 markers were available on both arrays and were therefore genotyped in the entire material. For the remaining 682,470 and for sporadic missing values we performed genotype imputation using the Impute 2 software [@pone.0070174-Howie1], with the Hapmap 2 (rel. 24 Build 36) as a reference.

All individuals in the same family were located on the same plate. Quality control was first performed separately for the two arrays. SNP markers with less than 97% call rate in either of the two arrays were excluded.

Mendelian errors were detected by PLINK [@pone.0070174-Purcell1], 125,874 family-wise mendelian inconsistencies were set to missing (in each family the genotypes were set to missing for all subjects if there were any mendelian inconsistencies for a specific SNP).

Statistical Analysis {#s4e}
--------------------

### Linkage {#s4e1}

For the linkage analysis only markers from both platforms were considered. From this set of 271,078 common SNP markers a LD pruned set of 105 539 SNPs were selected using PLINK. Parameters were a window size of 50 and R^2^\<0.5. The Decode genetic map as supplied by Illumina was used to run non-parametric linkage using Merlin version 1.1.2 [@pone.0070174-Abecasis1] with the NPL all method [@pone.0070174-Whittemore1]. Marker allele frequencies were estimated from the founders.

### Transmission Disequlibrium Test (TDT) {#s4e2}

Spielman et al introduced the Transmission Disequilibrium Test (TDT) in 1993 [@pone.0070174-Spielman1].

The imputation analysis provides us with (posterior) probabilities for each of the possible genotypes at each locus and to utilize all posterior probabilities, we performed an analysis where we use the expected values of the transmission counts. The test statistic will then have the following form,

has approximately the same distribution as the test statistic *T* in [@pone.0070174-Spielman1].

### Stratified TDT {#s4e3}

We implement a stratified TDT analysis where trios are split into a low-risk and a high-risk group based on the HLA genotype of the affected offspring. Children carrying the HLA-DQA1\*02/05 risk allele and homozygous for the HLA-DQB1\*02 risk allele (i.e. individuals carrying the DR3/DR3 or the DR3/DR7 haplotypes) were put in the "high-risk" group and the remaining children were put in the "low-risk" group. The rationale behind this is explained in the introduction and further information about this stratification can be found in our previous Linkage study [@pone.0070174-Naluai2]. A standard TDT analysis, with the 0.95 cut-off for imputation probabilities, was applied to each of these groups using PLINK [@pone.0070174-Purcell1].

### Test for two-locus interaction {#s4e4}

To examine possible interactions between marker variants, we used a pairwise test based on the one introduced by Kotti [@pone.0070174-Kotti1]. Consider two biallelic markers without linkage disequilibrium between their alleles. In the general model M~G~ the penetrance matrix has 9 parameters,

Let **n** be the 3×3 matrix of genotype counts among the cases for the two markers, and let **m** be the corresponding matrix for the non-transmitted allele combinations. The likelihood for the models is

For this analysis we use one affected subject from each family and markers were chosen based on the expected counts TDT ([equation 1](#pone.0070174.e001){ref-type="disp-formula"}) and three different inclusion criteria:

1.  P-value less than 3.0×10^−4^.

2.  P-value less than 0.01 in our analysis and with a p-value less than 0.05 in the GWAS by Dubois et al. [@pone.0070174-Dubois1] and if the product of these p-values were less than 5.0×10^−5^ and the association were in the same allelic direction.

3.  An allele transmission ratio of \<0.2 or \>5 combined with a p-value less than 2×10^−3^.

We defined 383 regions using the inclusion criteria above ([Fig. 2](#pone-0070174-g002){ref-type="fig"} and [Table S1](#pone.0070174.s001){ref-type="supplementary-material"}) a region consisted of a set of markers where the distance between adjacent markers was less than 100 kb. With these regions defined we analyzed all pairwise interactions using a *Likelihood Ratio* (LR) tests comparing the following four models:

-   M~0~: None of the two loci is associated with CD,

-   M~R~: Heterogeneity model [@pone.0070174-Rice1], with penetrance

where α~i~ and β~j~ are the penetrance factors for the genotypes A~i~ and B~j~ [@pone.0070174-Risch3] respectively.

-   M~M~: Multiplicative model,

-   M~G~: the general model.

The restricted model used in [@pone.0070174-Kotti1] is the multiplicative model. We use the M~G~-versus-M~M~ test to filter out false positives, based on that if one or both of the SNPs were marginally significant by chance, then the joint distribution (penetrance) of these markers should follow a multiplicative model.

We have the likelihood ratio statistic will follow a *x* ^2^ distribution under the restricted model if M~j~ is nested in M~k~. The maximum likelihood estimates of the penetrance parameters and allele frequencies do not have a simple explicit expression, so to maximize the likelihoods we use the function *optim* in the statistical software R.

Gene Selection {#s4f}
--------------

Out of the 603 SNPs selected from the three inclusion criteria ([Fig. 2](#pone-0070174-g002){ref-type="fig"} and [Table S1](#pone.0070174.s001){ref-type="supplementary-material"}), we were able to identify genes surrounding 444 SNPs using GRAIL [@pone.0070174-Raychaudhuri1]. Grail uses known recombination hotspots in order to limit the region of interest surrounding each SNP marker. Genes around the remaining SNPs were identified with the Genome Browser (<http://genome.ucsc.edu>) and the 5 closest genes within 250 kb from the associated SNPs were included. In cases where there were no genes within this distance we included the closest gene.

Pathway Analysis {#s4g}
----------------

We analyzed connections between genes in different regions, using GeneTrail [@pone.0070174-Backes1] and the Ingenuity Pathway Analysis (IPA) software (Ingenuity Inc. CA, USA). Within each associated region, all but one gene from the same gene family were removed. This was done in order not to amplify the significance of homologous gene clusters, (i.e. chemokine receptor-, interferon- and histone-gene clusters).

URLs {#s4h}
----

PLINK (<http://pngu.mgh.harvard.edu/purcell/plink/>)

KEGG ([www.genome.jp/kegg/](http://www.genome.jp/kegg/))

Gene Ontology ([www.geneontology.org/](http://www.geneontology.org/)).

GWAS catalog, <http://www.genome.gov/gwastudies/>

GRAIL (<http://www.broadinstitute.org/mpg/grail/>)

SNAP (<http://www.broadinstitute.org/mpg/snap/ldplot.php/>)

GeneTrail (<http://genetrail.bioinf.uni-sb.de/>)
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**A selection of 603 top associated SNPs and the two top HLA SNPs.** Based on three inclusion criteria, 603 SNP markers and 383 regions were identified. Our TDT results, where T and U are the expected transmission counts (based on all the posterior imputation probabilities) and corresponding results from Dubois et al. [@pone.0070174-Dubois1].
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